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ABSTRACT  
Objective: To compare efficacy of pharmacotherapies for chronic idiopathic constipation (CIC) 
based on comparisons to placebo using Bayesian network meta-analysis. 
Data Sources: We conducted searches (inception to May 2015) of MEDLINE, EMBASE, 
Scopus and Cochrane Central, as well as original data from authors or drug companies for the 
medications used for CIC.  
Study Selection: Phase IIB and phase III randomized, placebo-controlled trials (RCT) of ≥4 
weeks’ treatment for CIC in adults with Rome II or III criteria for functional constipation; trials 
included at least 1 of 4 endpoints. 
Data Extraction and Synthesis: Two investigators independently evaluated all full text articles 
that met inclusion criteria and extracted data for primary and secondary endpoints, risk of bias 
and quality of evidence. 
Outcomes: Primary endpoints were ≥3 complete spontaneous bowel movements (CSBM)/week 
and increase over baseline by ≥1 CSBM/week. Secondary endpoints were change from baseline 
(∆b) in the number of SBM/week and ∆b CSBM/week.  
Results: Twenty-one RCTs (9189 patients) met inclusion and endpoint criteria: 9 prucalopride, 3 
lubiprostone, 3 linaclotide, 2 tegaserod, 1 each velusetrag, elobixibat, bisacodyl and sodium 
picosulphate (NaP). All pre-specified endpoints were unavailable in 4 polyethylene glycol 
studies. Bisacodyl, NaP, prucalopride and velusetrag were superior to placebo for the ≥3 
CSBM/week endpoint. No drug was superior at improving the primary endpoints on network 
meta-analysis. Bisacodyl appeared superior to the other drugs for the secondary endpoint, ∆b in 
number of SBM/week.   
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Conclusions: Current drugs for CIC show similar efficacy. Bisacodyl may be superior to 
prescription medications for ∆b in the number of SBM/week in CIC.    
 
  
Page 4 of 72
https://mc.manuscriptcentral.com/gut
Gut
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
Nelson, Camilleri, et al. - 5 - 
 
 
SUMMARY BOX 
What is already known about this subject? 
-  Fifty percent of patients with chronic idiopathic constipation (CIC) are not completely satisfied 
with treatment, especially with fiber and laxatives. 
-  The number needed to treat (NNT), estimated from placebo-controlled clinical trials in CIC 
comparing pharmacological therapies to placebo, have been reported as follows: osmotic and 
stimulant laxative, NNT 3; lubiprostone, NNT 4; and prucalopride and linaclotide, both NNT 6. 
-  The absence of direct comparisons between different drug classes limits comparison of 
efficacy among treatments.  
What are the new findings? 
-  Current drugs for CIC show similar efficacy for primary endpoints, which were ≥3 complete 
spontaneous bowel movements (CSBM)/week and increase over baseline by ≥1 CSBM/week. 
-  Bisacodyl may be superior to prescription medications for change from baseline (∆b) 
SBM/week in CIC and in comparison with some of the drugs in ∆b CSBM/week.  
How might it impact on clinical practice in the foreseeable future? 
-  Head-to-head trials of active agents are necessary to determine the optimal selection of 
pharmacological agents for CIC. 
-  Alternatively, first line medications for patients with CIC should be according to the 
pathophysiology in order to increase efficacy, such as prokinetics for patients with documented 
slow transit constipation in the absence of rectal evacuation disorders. 
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INTRODUCTION 
The estimated global prevalence of chronic idiopathic constipation (CIC) in adults is 
14%.[1] It is usually diagnosed using Rome III symptom criteria,[2] is about twice as common in 
women and more prevalent over 65 years of age, significantly impacts quality of life, and 
constitutes a significant financial burden.[3] Treatment of constipation [4] usually starts with  
nonpharmacological agents like fiber (soluble in preference to nonsoluble fiber and is followed 
by pharmacological agents if there is no response to fiber.[5] Polyethylene glycol, an osmotic 
laxative, increases the mean number of stools per week more effectively than placebo or 
lactulose in adults with CIC, based on direct meta-analyses.[6] It is estimated that about 50% of 
patients with CIC were not completely satisfied with treatment due to lack of efficacy or safety 
concerns, especially with fiber and laxatives (both stimulant and osmotic). 
Therefore, this appraisal of the relative efficacy of pharmacotherapies for chronic CIC is 
clinically relevant. The pharmacological classes of the medications used for CIC are: diphenyl 
methanes or derivatives (bisacodyl and sodium picosulphate), 5-HT4 receptor agonists 
(prucalopride, tegaserod and velusetrag), guanylate cyclas  C receptor agonist (linaclotide), 
chloride channel type 2 opener (lubiprostone) and apical sodium bile acid, (also known as ileal 
bile acid transport) inhibitor (elobixibat).  
The numbers needed to treat (NNT), estimated from placebo-controlled clinical trials 
comparing these medications to placebo in CIC, were reported as follows: osmotic and stimulant 
laxative, NNT 3; lubiprostone, NNT 4; and  prucalopride and linaclotide, both NNT 6.[6] This 
might suggest differences in efficacy of the different drug classes; however, this assessment was 
based on failure to respond to therapy, and vastly different endpoints were used in individual 
studies.  
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The absence of direct comparisons between different drug classes limits comparison of 
efficacy among treatments to the endpoints currently recommended by the US Food and Drug 
Administration and is consistent with those of European Medicines Agency.[7] Therefore, our 
aim was to compare the efficacy of drugs for CIC based on results of each drug compared to 
placebo using Bayesian network meta-analysis and endpoints consistent with current regulatory 
agency recommendations. 
METHODS 
This systematic review and network meta-analysis was performed according to guidance 
provided by the Cochrane Handbook for Systematic Reviews of Interventions [8]. It is reported 
according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) guidelines[9]. We followed an a priori established protocol. 
Search Methods for Identification of Studies 
A thorough database search was done in May 2015, using Ovid MEDLINE In-Process & 
Other Non-Indexed Citations and Ovid MEDLINE (1946 to present), Ovid EMBASE, Scopus 
databases (1988 to 2015) and Ovid Cochrane CENTRAL (to March 2015) for all the drugs used 
for treatment of CIC. An expert librarian (PE) conducted the medical literature search with input 
from the investigators. All the studies for this meta-analysis were identified using a combination 
of subject headings and free text terms including constipation, chronic constipation, functional 
constipation, lubiprostone, linaclotide, plecanatide, bisacodyl, sodium picosulfate (NaP), 
prucalopride, velusetrag, naronapride, polyethylene glycol (PEG), lactulose, elobixibat, fiber, 
and randomized placebo-controlled trial. Terms were searched  in the title, abstract, original title, 
name of substance word, subject heading word, keyword heading word, protocol supplementary 
concept word, rare disease supplementary concept word, and unique identifier. The search was 
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conducted using combinations of these terms by using “and/or”. Multiple different combinations 
of these terms were used. All the abstracts identified using the search strategy were 
independently evaluated by two investigators (AN and NV) in order to select studies that were 
eligible for inclusion. For those studies, full text articles were requested. Additional studies were 
added after review of these drugs in the treatment of CIC in clinicaltrials.gov and manual review 
of the citations in the publications. All the studies were independently identified by two 
investigators using well-defined inclusion criteria; conflicts were resolved by consensus between 
the two investigators after discussing with a third investigator (MC) with content expertise.  
Inclusion Criteria  
This systematic review and network meta-analysis was limited only to randomized, 
placebo-controlled trials of drugs that are either approved by FDA for CIC or drugs with data 
available for at least one pre-specified endpoint from phase IIB or III randomized, placebo-
controlled trials, and  >4 weeks of treatment. Participants included were adults (>18 years of age) 
who satisfied Rome II or Rome III criteria for (chronic) functional constipation.  
There were no exclusions based on gender, sample size, medical condition, language 
limitation or medications that are known to affect colonic transit or minimum follow-up period. 
All eligible studies were required to have placebo as control interv ntion.  
Outcome Assessment 
The current recommended endpoint required by regulatory agencies (specifically, the 
U.S. Food and Drug Administration) for demonstration of efficacy in CIC trials is ≥3 complete 
spontaneous bowel movements (CSBM)/week and increase over baseline by ≥1 CSBM/week in 
9 out of 12 weeks of treatment. However, only randomized, placebo-controlled trials of 
linaclotide included this endpoint; therefore, we analyzed different endpoints that addressed 
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similar outcomes, in order to be consistent in appraising efficacy among studies. The primary 
endpoints were the proportion of responders, based on ≥3 CSBM)/week or the proportion of 
responders with increase over baseline by ≥1 CSBM/week.  The secondary endpoints were 
continuous, quantitative variables: the change from baseline (∆b) in the number of spontaneous 
bowel movements (SBM)/week and ∆b CSBM/week. Unfortunately, none of the four available 
PEG trials included the endpoints selected for our network meta-analysis. 
Data Extraction and Management   
Data extraction from the eligible studies was performed by two independent investigators 
(AN and SC) for the primary and secondary endpoints. Authors of the original publications were 
contacted by email or by phone requesting missing data in the eligible studies. Data were 
extracted from manuscripts or databases provided by the investigators or drug companies. Data 
for primary endpoints were extracted as number of responders and non-responders for each 
primary endpoint and mean and standard deviation for secondary endpoints.  
We also collected data about characteristics of the randomized, placebo-controlled trials, 
such as study center location (by continents); total number, age and gender of participants in the 
intervention and control groups; type of intervention; duration of therapy; and criteria for a 
diagnosis of constipation. Finally, data were extracted to appraise study quality, such as method 
used for analysis of missing data and loss of follow-up in the intervention and control groups.  
Statistical Analysis 
We calculated relative risk for dichotomized outcomes, weighted mean difference 
(WMD) for continuous outcomes, and related confidence intervals. We performed head-to-head 
comparisons using DerSimonian-Laird random-effects model. We assessed statistical 
heterogeneity using the I2 statistic, which represents the proportion of heterogeneity that is not 
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the result of chance, but reflects true differences across study populations and interventions; I2 
>50% indicates substantial heterogeneity. Direct comparisons were performed using RevMan 
v5.3 (The Nordic Cochrane Centre Copenhagen, Denmark). 
Network meta-analyses were used to combine effect sizes for all possible comparisons 
(direct and indirect), regardless of whether they had been compared in trials. In contrast to 
traditional meta-analyses, which compare one intervention with another one at a time and 
combine evidence directly from head-to-head clinical trials (if such trials exist), the network 
meta-analyses allow comparison of all interventions simultaneously. A multivariate meta-
regression model developed by White was used.[10] The network meta-analyses were conducted 
using the “network” suite in Stata Version 14.0 (StataCorp LP, College Station, TX, USA).[10]   
Sensitivity Analysis 
We examined the effects of the drugs for CIC based on relative risks of the primary and 
secondary endpoints. We evaluated effect sizes based on therapeutic dose (standard dose group 
versus high dose) and study quality for prucalopride (low risk of bias versus high risk of bias) for 
CIC treatment. We also applied the “leave-one-out” method by excluding one study of 24 weeks 
duration to evaluate the robustness of our findings.   
Assessment of Risk of Bias and Publication Bias 
Risk of bias was assessed using Cochrane Handbook for Assessing the Risk of Bias [9].  
Two investigators (AN and PV) independently assessed the randomization schedule, allocation 
concealment, blinding of participants and investigators, blinding of outcome assessment, 
methods used for missing data, selective reporting, incomplete outcome data, risk of bias for 
primary and secondary endpoints, and loss of follow up during the treatment period. Due to the 
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limited number of studies included in the analyses, we were not able to evaluate potential 
publication bias.[11]  
Quality of Evidence 
We used the Grading of Recommendation, Assessment, Development and Evaluation 
(GRADE) Approach to rate the quality of evidence for the estimates derived from the network 
meta-analyses.[12] Since the studies included were only randomized, placebo-controlled trials, 
the quality of evidence was considered high in the beginning and down rated based on the 
assessment of risk of bias, inconsistency, indirectness, imprecision and publication bias. The 
quality of evidence is rated as high, moderate, low and very low. For indirect estimates, the 
rating usually starts at lowest rating of contributing direct evidence and can be further down 
rated based on imprecision and indirectness (mainly intransitivity, i.e., difference in patient 
populations between studies involved).  
RESULTS 
Search Results 
The search strategy used identified 546 citations and, among these, we identified 114 
articles for review for the full text appraisal. Among the 114 articles, only 18 articles met the 
inclusion criteria; 96 studies did not meet the inclusion criteria, most often because the endpoints 
in the trials were different from the selected primary and secondary endpoints, articles did not 
have original data, or they were nonrandomized studies. The agreement between the 
investigators (AN and NV) for selection of studies after full text review was high (Kappa statistic 
0.86). 
Three studies which were not identified by the search strategy were added by the 
investigators. We contacted the authors and drug sponsors of these studies for additional 
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information regarding the primary and secondary endpoints, and their responses were added to 
the analysis. 
Figure 1 shows the schematic diagram of study selection for the systematic review and 
meta-analysis; in total, 21 studies were eligible. The study characteristics are summarized in 
Table 1.  
There were 9189 patients in the 21 studies: 9 with prucalopride,[13, 14, 15, 16, 17, 18, 
19, 20, 21] 3 with lubiprostone,[22, 23, 24] 3 with linaclotide,[25, 26, 27] 2 with tegaserod,[28, 
29] 1 each with Velusetrag,[30] Elobixibat,[31] bisacodyl,[32] and sodium (Na) 
picosulphate.[33] The number of drugs, sample size of each drug, and the number of clinical 
trials included in the network meta-analysis are represented in the form of a network diagram 
(Figure 2).  
The risk of bias of the included studies is summarized in Table 2. Overall, quality was 
high in 11, moderate in 9, and low in 1 study. Downgrading of quality was based most often on 
unstated details regarding blinding, allocation concealment or management of missing data. 
Direct Meta-analysis 
The results of the direct meta-analysis for each primary and secondary endpoint are 
summarized in Figure 3A-D.  
Primary Endpoints  
The data for responder analysis with ≥3 CSBM/week were available for 14 randomized, 
placebo-controlled trials. All six drugs showed a significant increase in ≥3 CSBM/week when 
compared to placebo. Among the three 5HT4 agonists (prucalopride, velusetrag and tegaserod), 
prucalopride showed higher efficacy [relative risk (RR)] of 1.85 with a 95% confidence interval 
(CI) of 1.35 to 2.54 when compared to placebo and with significant heterogeneity of 80.8% 
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(p=0.0001). Velusetrag had an RR of 4.86 (95% CI, 2.02 to 11.71); the wider confidence interval 
may suggest velusetrag might be less efficacious when compared to prucalopride. Stimulant 
laxatives, bisacodyl and NaP, showed approximately similar efficacy. For linaclotide, RR was 
1.96 (95% CI, 1.12 to 3.44). There was significant heterogeneity between studies of all the drugs 
appraised using this endpoint (I2 = 77.4% P < 0.00001). 
For responder analysis with increase over baseline by ≥1 CSBM/week, data were 
available for 15 randomized, placebo-controlled trials; all 7 of the drugs were superior to 
placebo. Stimulant laxatives (bisacodyl and NaP) and elobixibat showed approximately similar 
efficacy. Prucalopride showed superior efficacy among the 5HT4 agonists, but the heterogeneity 
between studies was significant (I2 = 74.5%, p=0.0001). Even though the RR for velusetrag was 
3.10, which is relatively high when compared to the RR for prucalopride, the 95% CI with 
velusetrag was wide (1.83 to 5.24) and overlapped that of prucalopride. Given the overlapping 
95% CI for the two drugs and the significant heterogeneity in the efficacy of prucalopride, the 
data show overall similar efficacy for prucalopride and velusetrag.  
Secondary Endpoints  
Data for ∆b CSBM/week were available only for 5 drugs. All the drugs showed superior 
efficacy when compared to placebo. Bisacodyl had a weighted mean difference (WMD) of 3.20 
(95% CI, 2.66 to 3.74). Elobixibat and NaP had similar efficacy. For linaclotide, the WMD was 
1.57, with heterogeneity I2 of 0%; this WMD was greater than that of prucalopride which was 
0.90 and was also associated with significant heterogeneity I2 of 76.8%.    
For the ∆b SBM/week, all 7 of the drugs showed superior efficacy relative to placebo. 
Bisacodyl showed higher efficacy with a WMD of 4.90 when compared to NaP (3.20). 
Velusetrag, elobixibat and linaclotide showed similar efficacy with a mean difference (MD) in 
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the absolute number of ∆b SBM/week of ~2.08. For prucalopride, the WMD was 2.03, with 
significant heterogeneity of 63.9%. For lubiprostone, WMD was 1.91 with an I2 of 23.4%. 
Network Meta-analysis 
Responder analysis for ≥3 CSBM/week (Table 3A)  
Except for tegaserod, all the other drugs (bisacodyl, NaP, prucalopride, velusetrag, 
linaclotide and elobixibat) showed superior efficacy compared to placebo, but none of the drugs 
showed superior efficacy when compared to each other in the network meta-analysis. 
Responder analysis for increase over baseline by ≥1 CSBM/week (Table 3B)  
Apart from tegaserod and linaclotide, all the drugs (bisacodyl, NaP, prucalopride and 
velusetrag) showed superior efficacy when compared to placebo, but none of the drugs showed 
superior efficacy when compared to each other in the network meta-analysis, with the exception 
of velusetrag which appears superior when compared to prucalopride and tegaserod. 
Change in number of CSBM/week compared to baseline (Table 4A) 
Bisacodyl, NaP, prucalopride, linaclotide and elobixibat showed superior efficacy on the 
∆b CSBM/week when compared to placebo. On a network meta-analysis, bisacodyl was superior 
to NaP, prucalopride and linaclotide. Bisacodyl did not show significant efficacy over elobixibat 
using this endpoint. NaP showed superior efficacy when compared to prucalopride.  
Change in number of SBM/week compared to baseline (Table 4B) 
When compared to placebo on a network meta-analysis, bisacodyl, NaP, prucalopride, 
velusetrag, linaclotide, elobixibat and lubiprostone treatment showed superior increase in 
∆b SBM/week.  
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Network meta-analysis suggested that bisacodyl is superior when NaP, prucalopride, 
velusetrag, linaclotide, elobixibat and lubiprostone are compared to bisacodyl. NaP showed 
superior efficacy when prucalopride and lubiprostone were compared to NaP.  
Quality of Evidence 
We applied the GRADE approach to the main outcome of ≥1 CSBM/week because it had 
the largest number of included trials. In terms of direct estimates of drugs compared to placebo, 
the quality of evidence was moderate or high for all comparisons. However, most head-to-head 
comparisons were imprecise (i.e., their CIs were wide and overlapped the null effect). Therefore, 
the quality of evidence of head-to-head comparisons was mostly low (Table 5).  
Sensitivity Analysis 
We conducted sensitivity analyses based on dose of medication (for all drugs for which at 
least two doses were studied) and risk of bias (for prucalopride). Results were consistent between 
standard therapeutic dose group compared to high and low dose groups for the primary endpoints 
and for most of the secondary endpoint analyses (Table 6). An exception was that low dose (in 
contrast to standard or high dose) prucalopride was not eff ctive compared to placebo for the 
endpoints of ≥3 CSBM/week and ∆b SBM/week.  
When analysis was restricted to prucalopride studies at low risk of bias, four trials[13, 16, 
18, 19] were included and, for the two primary responder analyses, we noted that for 
>3 CSBM/week, the RR was 2.12 (1.71, 2.63) and, for increase over baseline by >1 
CSBM/week, the RR was 1.76 (1.54, 2.02); both had heterogeneity of 0%.  
A third sensitivity analysis assessed whether any one study with a markedly different 
duration [17] had a dominant effect on the pooled RR or heterogeneity. We found that this single 
study did not markedly affect the summary estimate for the prucalopride studies. Thus, including 
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the study resulted in RRs for ≥3 CSBM/week and for increase over baseline by ≥1 CSBM/week 
of 1.85 (I2 80.8%) and 1.54 (I2 74.3%), respectively; excluding the study, the RRs were 1.96 (I2 
81.8%) and 1.63 (I2 66.4%), respectively.  
DISCUSSION 
Our study has shown that each drug used in the treatment of CIC is superior to placebo, 
based on the published randomized, placebo-controlled trials. All the drugs are equally 
efficacious for the primary endpoints of responder analysis with ≥3 CSBM/week and increase 
over baseline by ≥1 CSBM/week, in the network meta-analysis. Bisacodyl may be superior to all 
the other drugs in the secondary endpoint of ∆b SBM/week and in comparison with some of the 
drugs in ∆b CSBM/week.  
There are, however, limitations in this appraisal of relatively greater efficacy of 
bisacodyl. There is only one bisacodyl trial with only 4 weeks of treatment compared to other 
drugs which provided treatment for 12 or 24 weeks. Confirmation of superiority of any of these 
pharmacotherapies requires direct comparisons of the active interventions using randomized, 
placebo-controlled trials. A network meta-analysis has distinct features in the absence of trials of 
direct comparisons of treatments, and may inform judicious selection of treatment. The 
International Society for Pharmacoeconomics and Outcomes Research (ISPOR) recommends use 
of multiple treatment meta-analyses in synthesis of data, even with nodal networks, as it allows 
for more statistically sound assessment of comparative efficacy.[34]  
Typically, patients in these randomized, placebo-controlled trials fulfilled Rome II or III 
criteria for constipation after exclusion of medical and structural conditions.[35] These 
symptom-based criteria do not differentiate groups, based on the pathophysiology causing CIC. 
Based on a study of symptoms and pathophysiology in 1411 patients, subgroups of CIC were 
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identified, based on pathophysiology: normal transit constipation (NTC) in ~70%, dyssynergic 
defecation in ~25%, and slow transit constipation (STC) in ~4.5%. [36] In fact, epidemiological 
studies also have shown that about one-third of people in the community who experience 
constipation endorse symptoms consistent with dyssynergic defecation.[4] With a preponderance 
of CIC patients being female and having NTC, the similar efficacy to all the classes of drugs for 
the treatment of CIC is not surprising.  
Prior randomized, placebo-controlled trials included in this analysis did not subgroup 
patients according to pathophysiology; hence, we are unable to report efficacy in subgroups of 
CIC. It is conceivable that patients with STC might respond better to treatment with agents that 
have significant effects on colonic motor function. Several of the agents evaluated in this 
network meta-analysis accelerate colonic transit, including intestinal secretagogues 
(lubiprostone,[37] linaclotide,[38] and the bile acid transport inhibitor, elobixibat [39]) and 
prokinetic agents (prucalopride,[40] tegaserod,[41] and bisacodyl [42]). However, among all 
these drugs, only prucalopride [43] and bisacodyl have been shown to increase the number of 
high amplitude propagated contractions (HAPC), which ar  highly propulsive in the colon.[44]  
Lubiprostone did not induce colonic high amplitude contractions.[45] 
A recent consensus monograph, based on meta-analysis of treatments of CIC, gave strong 
recommendation for treatment with fiber, osmotic laxatives (PEG, lactulose), stimulant laxatives 
(NaP and bisacodyl), prucalopride, linaclotide and lubiprostone.[46] However, the quality of 
evidence was considered moderate in some of the trials, there were no direct comparisons 
between active drugs, and the analysis used as primary endpoint the failure to respond to therapy. 
This appraisal actually combined in non-responder status failure to respond to different endpoints 
in each trial. In addition, the secondary endpoints evaluated did not differentiate SBM from 
Page 17 of 72
https://mc.manuscriptcentral.com/gut
Gut
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
Nelson, Camilleri, et al. - 18 - 
 
 
CSBM. Despite these methodological differences, our direct and network meta-analyses confirm 
the general conclusion of the prior report regarding the efficacy of each intervention relative to 
placebo with reference to the primary endpoints (which are the components of the endpoint 
currently recommended by FDA), although there is a possible difference in efficacy on 
secondary endpoints between bisacodyl and other drugs.  
Our study has some limitations. There is only one randomized, placebo-controlled trial 
for 4 of the drugs included in the meta-analysis (NaP, bisacodyl, velusetrag and elobixibat), and 
osmotic laxatives such as PEG, lactulose, and magnesium salts were not included, since the 
endpoints in those studies were not uniform or consistent with the inclusion criteria. This 
particularly applies to the trials with PEG.[47, 48, 49, 50] There is one randomized, placebo-
controlled trial directly comparing PEG3350 + electrolytes (PEG3350+E) to prucalopride 
treatment,[51] but this was a single-center study conducted in a controlled environment on 
patients many of whom had features suggesting evacuation disorder at baseline: ~50% reported 
sensation of anal blockage and 15% manual maneuvers to facilitate defecation. Moreover, the 
primary endpoint was the proportion of patients having ≥3 SCBMs during the last week of 
treatment in a 4-week trial, rather than the entire treatment period, and the randomized, placebo- 
controlled trial showed non-inferiority of PEG3350 + E to prucalopride, consistent with our 
general conclusion that the approved pharmacotherapies for CIC have similar efficacy.  
Other limitations in our network meta-analysis are the variability in the duration of 
treatment (4 to 24 weeks) and safety and adverse events for the drugs were not analyzed in our 
study. Another limitation is that, in many of these pivotal clinical trials, bisacodyl is often used 
as the rescue medication, and the impact of this on the “placebo” arms could not be appraised as 
it is not reported in detail in the trials. It is also conceivable that the high number of prucalopride 
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trials impacted the relative assessment of efficacy by reducing the width of the confidence 
interval of the RR; therefore, we have interpreted cautiously the RR differences between 
prucalopride and velusetrag which was the only medication identified as less efficacious than 
prucalopride in the statistical analysis.   
Strengths in our study design and network meta-analysis include trials with similar 
patient population, comparators, outcome assessments, and trial design; application of the 
GRADE approach to provide an objective and transparent assessment of the quality of evidence 
for evaluating comparative efficacy of these agents;[52] and the inclusion of  the responder 
analyses as well as secondary endpoints which are very relevant in view of differences in 
baseline SBM and CSBM between studies.[53]  
In conclusion, network meta-analysis shows that current pharmacotherapies for CIC have 
similar efficacy. Based on secondary endpoints, bisacodyl may be superior to other medications 
prescribed for CIC; however, bisacodyl is associated with abdominal cramps and diarrhea. In the 
future, head-to-head trials of active agents are necessary to determine the efficacy and adverse 
effects in order to facilitate optimal selection of pharmacological agents for CIC instead of the 
current choice based on failure of prior drugs. 
  
Page 19 of 72
https://mc.manuscriptcentral.com/gut
Gut
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
Nelson, Camilleri, et al. - 20 - 
 
 
Acknowledgements: We thank Dr. Fabio Cataldi and Dr. Debra Silberg (Shire Pharmaceuticals, 
Turnhout, Belgium), the late Dr. Hans Graffner (Albireo, Göteborg, Sweden), Dr. Sabine 
Niedermeier (Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany), Dr. Peter 
Lichtlen (Sucampo AG, Bethesda, MD), Dr. Fukudo Shin (Tohoku University, Sendai, Japan), 
Dr. Michael A Kamm (University of Melbourne, Melbourne, Australia) and Dr. Stefan Mueller-
Lissner (Lehrkrankenhaus der Charité, Universitätsmedizin, Berlin, Germany) for providing 
access to clinical trial data for medications reviewed in this article. 
 
Funding:  Dr. Camilleri is supported by grant R01-DK92179 from National Institutes of Health 
for studies on lower functional gastrointestinal disorders.    
 
Competing Interests: Dr. Camilleri received grants for research on pharmacodynamics of 
prucalopride, velusetrag, elobixibat, linaclotide, and lubiprostone in the past decade. Dr. 
Camilleri serves as an advisor to Albireo, Rhythm, and Theravance, with compensation for his 
time serving as an advisor paid to his employer, Mayo Clinic, not to himself personally. 
The other authors have no competing interests. 
 
Authors’ contributions: 
Alfred D. Nelson:  concept development, data analysis, selection of articles, authorship   
Michael Camilleri:  concept development, data analysis, selection of articles, authorship   
Sakkarin Chirapongsathorn:  network meta-analysis, authorship  
Priya Vijayvargiya:  assessment of study quality, authorship 
Nelson Valentin:  selection of articles to be included after the literature search, authorship 
Andrea Shin:  analysis of data on 5HT4 agonists, authorship   
Patricia J. Erwin:  literature search for systematic review, authorship 
Zhen Wang:  network meta-analysis, authorship  
M. Hassan Murad:  systematic review and network meta-analysis, authorship 
 
  
Page 20 of 72
https://mc.manuscriptcentral.com/gut
Gut
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
Nelson, Camilleri, et al. - 21 - 
 
 
References 
 
1 Suares NC, Ford AC. Prevalence of, and risk factors for, chronic idiopathic constipation 
in the community: systematic review and meta-analysis. Am J Gastroenterol 2011;106:1582-91; 
quiz 1, 92. 
2 Longstreth GF, Thompson WG, Chey WD, et al. Functional Bowel Disorders. 
Gastroenterology 2006;130:1480-91. 
3 Peery AF, Crockett SD, Barritt AS, et al. Burden of Gastrointestinal, Liver, and 
Pancreatic Diseases in the United States. Gastroenterology 2015;149:1731-41.e3. 
4 Bharucha AE, Pemberton JH, Locke III GR. American Gastroenterological Association 
Technical Review on Constipation. Gastroenterology 2013;144:218-38. 
5 Voderholzer WA, Schatke W, Muhldorfer BE, et al. Clinical response to dietary fiber 
treatment of chronic constipation. Am J Gastroenterol 1997;92:95-8. 
6 Ford AC, Suares NC. Effect of laxatives and pharmacological therapies in chronic 
idiopathic constipation: systematic review and meta-analysis. Gut 2011;60:209-18. 
7           http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/ 
2014/02/WC500162134.pdf 
8 Higgins JP, Strene JAC. Cochrane Handbook for Systematic Reviews of interventions In: 
Higgins JP and Green S ed. Available from www.cochrane-handbook.org.: The Cochrane 
Collaboration; 2011. 
9 Hutton B, Salanti G, Caldwell DM, et al. The PRISMA Extension Statement for 
Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care 
Interventions: Checklist and ExplanationsPRISMA Extension for Network Meta-analysis. 
Annals of Internal Medicine 2015;162:777-84. 
10 White IR, Barrett JK, Jackson D, et al. Consistency and inconsistency in network meta-
analysis: model estimation using multivariate meta-regression. Research Synthesis Methods 
2012;3:111-25. 
11 Ioannidis JP, Trikalinos TA. The appropriateness of asymmetry tests for publication bias 
in meta-analyses: a large survey. CMAJ 2007;176:1091-6. 
12 Guyatt G, Oxman AD, Sultan S, et al. GRADE guidelines: 11. Making an overall rating 
of confidence in effect estimates for a single outcome and for all outcomes. Journal of Clinical 
Epidemiology 2013;66:151-7. 
13 Camilleri M, Kerstens R, Rykx A, et al. A Placebo-Controlled Trial of Prucalopride for 
Severe Chronic Constipation. New England Journal of Medicine 2008;358:2344-54. 
14 Coremans G, Kerstens R, De Pauw M, et al. Prucalopride is effective in patients with 
severe chronic constipation in whom laxatives fail to provide adequate relief. Results of a 
double-blind, placebo-controlled clinical trial. Digestion 2003;67:82-9. 
15 Ke M, Zou D, Yuan Y, et al. Prucalopride in the treatment of chronic constipation in 
patients from the Asia-Pacific region: a randomized, double-blind, placebo-controlled study. 
Neurogastroenterology & Motility 2012;24:999-e541. 
16 Müller-lissner S, Rykx A, Kerstens R, et al. A double-blind, placebo-controlled study of 
prucalopride in elderly patients with chronic constipation. Neurogastroenterology & Motility 
2010;22:991-e255. 
17 Piessevaux H, Corazziari E, Rey E, et al. A randomized, double-blind, placebo-controlled 
trial to evaluate the efficacy, safety, and tolerability of long-term treatment with prucalopride. 
Neurogastroenterology & Motility 2015;27:805-15. 
Page 21 of 72
https://mc.manuscriptcentral.com/gut
Gut
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
Nelson, Camilleri, et al. - 22 - 
 
 
18 Quigley EMM, Vandeplassche L, Kerstens R, et al. Clinical trial: the efficacy, impact on 
quality of life, and safety and tolerability of prucalopride in severe chronic constipation – a 12-
week, randomized, double-blind, placebo-controlled study. Alimentary Pharmacology & 
Therapeutics 2009;29:315-28. 
19 Tack J, van Outryve M, Beyens G, et al. Prucalopride (Resolor) in the treatment of severe 
chronic constipation in patients dissatisfied with laxatives. Gut 2009;58:357-65. 
20 Emmanuel AV, Roy AJ, Nicholls TJ, et al. Prucalopride, a systemic enterokinetic, for the 
treatment of constipation. Alimentary Pharmacology & Therapeutics 2002;16:1347-56. 
21 Yiannakou Y, Piessevaux H, Bouchoucha M, et al. A Randomized, Double-Blind, 
Placebo-Controlled, Phase 3 Trial to Evaluate the Efficacy, Safety, and Tolerability of 
Prucalopride in Men With Chronic Constipation. Am J Gastroenterol 2015;110:741-8. 
22 Johanson JF, Morton D, Geenen J, et al. Multicenter, 4-Week, Double-Blind, 
Randomized, Placebo-Controlled Trial of Lubiprostone, a Locally-Acting Type-2 Chloride 
Channel Activator, in Patients With Chronic Constipation. Am J Gastroenterol 2008;103:170-7. 
23 Barish CF, Drossman D, Johanson JF, et al. Efficacy and safety of lubiprostone in 
patients with chronic constipation. Dig Dis Sci 2010;55:1090-7. 
24 Fukudo S, Hongo M, Kaneko H, et al. Lubiprostone Increases Spontaneous Bowel 
Movement Frequency and Quality of Life in Patients With Chronic Idiopathic Constipation. 
Clinical Gastroenterology and Hepatology 2015;13:294-301.e5. 
25 Lacy BE, Schey R, Shiff SJ, et al. Linaclotide in Chronic Idiopathic Constipation Patients 
with Moderate to Severe Abdominal Bloating: A Randomized, Controlled Trial. PLoS ONE 
2015;10:e0134349. 
26 Lembo AJ, Kurtz CB, MacDougall JE, et al. Efficacy of Linaclotide for Patients With 
Chronic Constipation. Gastroenterology 2010;138:886-95.e1. 
27 Lembo AJ, Schneier HA, Shiff SJ, et al. Two Randomized Trials of Linaclotide for 
Chronic Constipation. New England Journal of Medicine 2011;365:527-36. 
28 Fried M, Johanson JF, Gwee KA, et al. Efficacy of Tegaserod in Chronic Constipation in 
Men. Am J Gastroenterol 2007;102:362-70. 
29 Kamm MA, Muller-Lissner S, Talley NJ, et al. Tegaserod for the Treatment of Chronic 
Constipation: A Randomized, Double-Blind, Placebo-Controlled Multinational Study. Am J 
Gastroenterol 2005;100:362-72. 
30 Goldberg M, Li YP, Johanson JF, et al. Clinical trial: the efficacy and tolerability of 
velusetrag, a selective 5-HT4 agonist with high intrinsic activity, in chronic idiopathic 
constipation – a 4-week, randomized, double-blind, placebo-controlled, dose–response study. 
Alimentary Pharmacology & Therapeutics 2010;32:1102-12. 
31 Chey WD, Camilleri M, Chang L, et al. A Randomized Placebo-Controlled Phase IIb 
Trial of A3309, A Bile Acid Transporter Inhibitor, for Chronic Idiopathic Constipation. Am J 
Gastroenterol 2011;106:1803-12. 
32 Kamm MA, Mueller–Lissner S, Wald A, et al. Oral Bisacodyl Is Effective and Well-
Tolerated in Patients With Chronic Constipation. Clinical Gastroenterology and Hepatology 
2011;9:577-83. 
33 Mueller-Lissner S, Kamm MA, Wald A, et al. Multicenter, 4-Week, Double-Blind, 
Randomized, Placebo-Controlled Trial of Sodium Picosulfate in Patients With Chronic 
Constipation. Am J Gastroenterol 2010;105:897-903. 
Page 22 of 72
https://mc.manuscriptcentral.com/gut
Gut
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
Nelson, Camilleri, et al. - 23 - 
 
 
34 Hoaglin DC, Hawkins N, Jansen JP, et al. Conducting indirect-treatment-comparison and 
network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment 
Comparisons Good Research Practices: part 2. Value Health 2011;14:429-37. 
35 Locke III GR, Pemberton JH, Phillips SF. AGA technical review on constipation. 
Gastroenterology 2000;119:1766-78. 
36 Nullens S, Nelsen T, Camilleri M, et al. Regional colon transit in patients with dys-
synergic defaecation or slow transit in patients with constipation. Gut 2012;61:1132-9. 
37 Camilleri M, Bharucha AE, Ueno R, et al. Effect of a selective chloride channel activator, 
lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy 
volunteers. American Journal of Physiology - Gastrointestinal and Liver Physiology 
2006;290:G942-G7. 
38 Andresen V, Camilleri M, Busciglio IA, et al. Effect of 5 Days Linaclotide on Transit and 
Bowel Function in Females With Constipation-Predominant Irritable Bowel Syndrome. 
Gastroenterology 2007;133:761-8. 
39 Wong BS, Camilleri M, McKinzie S, et al. Effects of A3309, an Ileal Bile Acid 
Transporter Inhibitor, on Colonic Transit and Symptoms in Females With Functional 
Constipation. Am J Gastroenterol 2011;106:2154-64. 
40 Bouras EP, Camilleri M, Burton DD, et al. Prucalopride accelerates gastrointestinal and 
colonic transit in patients with constipation without a rectal evacuation disorder. 
Gastroenterology 2001;120:354-60. 
41 Prather CM, Camilleri M, Zinsmeister AR, et al. Tegaserod accelerates orocecal transit in 
patients with constipation-predominant irritable bowel syndrome. Gastroenterology 
2000;118:463-8. 
42 Manabe N, Cremonini F, Camilleri M, et al. Effects of bisacodyl on ascending colon 
emptying and overall colonic transit in healthy volunteers. Alimentary Pharmacology & 
Therapeutics 2009;30:930-6. 
43 Miner P, Camilleri M, Burton D, et al. Prucalopride induces high amplitude propagated 
contractions in the colon of patients with chronic constipation: A randomized study. 
Neurogastroenterology and Motility 2015;27:86-. 
44 Preston DM, Lennard-Jones JE. Pelvic motility and response to intraluminal bisacodyl in 
slow-transit constipation. Dig Dis Sci 1985;30:289-94. 
45 Sweetser S, Busciglio IA, Camilleri M, et al. Effect of a chloride channel activator, 
lubiprostone, on colonic sensory and motor functions in healthy subjects. American Journal of 
Physiology - Gastrointestinal and Liver Physiology 2009;296:G295-G301. 
46 Ford AC, Moayyedi P, Lacy BE, et al. American College of Gastroenterology 
Monograph on the Management of Irritable Bowel Syndrome and Chronic Idiopathic 
Constipation. Am J Gastroenterol 2014;109:S2-S26. 
47 DiPalma JA, Cleveland MB, McGowan J, et al. A comparison of polyethylene glycol 
laxative and placebo for relief of constipation from constipating medications. South Med J 
2007;100:1085-90. 
48 DiPalma JA, Cleveland Mv, McGowan J, et al. A Randomized, Multicenter, Placebo-
Controlled Trial of Polyethylene Glycol Laxative for Chronic Treatment of Chronic 
Constipation. Am J Gastroenterol 2007;102:1436-41. 
49 Corazziari E, Badiali D, Bazzocchi G, et al. Long term efficacy, safety, and tolerabilitity 
of low daily doses of isosmotic polyethylene glycol electrolyte balanced solution (PMF-100) in 
the treatment of functional chronic constipation. Gut 2000;46:522-6. 
Page 23 of 72
https://mc.manuscriptcentral.com/gut
Gut
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
Nelson, Camilleri, et al. - 24 - 
 
 
50 Corazziari E, Badiali D, Habib FI, et al.. Small volume isosmotic polyethylene glycol 
electrolyte balanced solution (PMF-100) in treatment of chronic nonorganic constipation. Dig 
Dis Sci 1996;41:1636-42. 
51 Cinca R, Chera D, Gruss HJ, et al. Randomised clinical trial: macrogol/PEG 
3350+electrolytes versus prucalopride in the treatment of chronic constipation - a comparison in 
a controlled environment. Alimentary Pharmacology & Therapeutics 2013;37:876-86. 
52 Puhan MA, Schünemann HJ, Murad MH, et al. A GRADE Working Group approach for 
rating the quality of treatment effect estimates from network meta-analysis. BMJ 2014;349. 
53 Bielefeldt K, Levinthal DJ, Nusrat S. Effective Constipation Treatment Changes More 
Than Bowel Frequency: A Systematic Review and Meta-Analysis. Journal of 
Neurogastroenterology and Motility 2016;22:31-45. 
 
 
 
 
 
 
 
Page 24 of 72
https://mc.manuscriptcentral.com/gut
Gut
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
Nelson, Camilleri, et al. - 25 - 
 
 
Table 1.  Study Characteristics  
Study ID Location Drug 
Doses 
tested 
Study 
Duration      
(weeks) 
Number Total: 
Intervention/ 
control Age (I) Age (C) 
Gender, 
F % Constipation criteria 
Camilleri 
2008 USA PRU 
2mg,  
4 mg QD  12 620: 411/209 48.0±14.3 48.9±13.0 87.1 
≤2 CSBM/week for 6 months, and 
Rome III criteria# 
Coremans 
2003 Belgium PRU 4 mg QD  4 53: 27/26 43.8±2.7 47.4±2.9 98.1 
≥2 of the following for 6 months: 2 
SBM/week and Rome III criteria# 
Ke 2012 
Asia-
pacific PRU 2mg QD  12 501: 249/252 
41.4±12.9
2 41.8±12.9 90 
≤2 SBM/week on average, and ≥1 of 
the following in Rome III criteria* 
Mueller-
Lissner 2010 Int PRU 
1mg, 
2mg,  
4 mg QD  4 300: 230/70 76.5±7.7 76±7.4 70.3 
≤2 CSBM/week for 6 months and ≥1 of 
the following in Rome III criteria# 
Piessevaux 
2015 Europe PRU 2mg QD  24 346: 177/169 49.4±15.8 48.3±16.3 14.7$ 
≤2 CSBM/week and ≥1 of the 
following  in Rome III criteria# for 6 
months  
Quigley 
2009 USA PRU 
2mg,  
4 mg QD  12 641: 429/212 48.9±13.9 46.2±13.0 86.6 
≤2 CSBM/week for 6 months and ≥1 of 
the following in Rome III criteria# for 6 
months 
Tack 2009 Int PRU 
2mg,  
4 mg QD  12 713: 473/240 44.1±15.1 43.7±15.3 90.8 
≤2 CSBM/week for 6 months and ≥1 of 
the following  in Rome III criteria# for 
6 months 
Emmanuel 
2002 UK PRU 1mg QD  4 74: 37/37 NA NA 100 
≤2 SBM/week and need to strain at 
least 25% of the defecation. 
Yiannnakou 
2015 Europe PRU 2mg QD 12 370: 184/186 58.4±17.6 58.5±16.3 0¶ 
≤2 CSBM/week for 6 months and ≥1 of 
the following  in Rome III criteria# for 
6 months 
Goldberg 
2010 USA VEL 
15mg, 
30mg, 
45mg 
QD  4 401: 294/107 44.4±11.7 45.4±10.0 92.0 
≥18 years of age satisfying Rome 3 
criteria functional constipation*  
Fried 2007 Int TEG 6mg bid  12 322: 158/164 51.1±17.1 51.8±17.2 0¶ 
≤3 CSBM/week and ≥1 of the 
following in Rome III criteria# for 6 
months 
Kamm 2005 Int TEG 
2mg, 
6mg bid  12 1264: 848/416 46.3±15.2 46.0±15.6 86.3 
≤3 CSBM/week and ≥1 of the 
following in Rome III criteria# for 6 
months 
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Barish 2010 USA LUBI 
24mcg 
bid  4 237: 119/118 NK NK 88.2 
≤3 SBM/week and ≥1 of the following 
in Rome III criteria# for 6 months 
Fukudo 
2015 Japan LUBI 
24mcg 
bid  4 124: 62/62 42.7±16.4 41.5±14.2 88 
Rome III criteria*, fewer than 3 
defecations per week. 
Johanson 
2008 USA LUBI 
24mcg 
bid  4 244: 120/124 48.0±12.3 49.1±12.9 89.7 
≤3 SBM/week and ≥1 of the following 
in Rome III criteria# for 6 months 
Chey 2011 USA ELO 
5, 10, or 
15mgQD  4 190: 143/47 47.6 49.9 89.5 
<3 CSBM/week and ≥2 of the 
following in Rome III criteria* 
Kamm 2011 UK BIS 
10mg 
QD 4 356: 239/117 55.8±15.9 54.7±15.1 74.7 
< 3 CSBM/week and ≥1 of the 
following in Rome III criteria# for 6 
months 
Mueller-
lissner  2010 Germany NaP 
10mg 
QD  4 362: 229/133 50.2±17.2 51.9±16.5 77.7 
< 3 CSBM/week on average and ≥1 of 
the following  in Rome III criteria# for 
6 months 
Lembo 2010 USA LINA 
75, 150, 
300, or 
600mcg 
QD  4 307: 239/68 47.6±13.1 46.1±15.6 92 
<3 SBM/week and ≥1 of the following  
in Rome III criteria# at least 12 weeks 
during the 12 months preceding the 
study 
Lembo 2011 
  
USA LINA 
145 or, 
290mcg, 
QD  
 
12 643: 434/209 47.4±14.2 49.3±14.3 87.4 < 3 SBM/week and ≥1 of the following 
Rome criteria# for at least 12 weeks 
within the preceding 12 months LINA 12 633: 418/215 47.2±12.8 47.0±13.5 90.4 
Lacy 2015 USA LINA 12 487: 314/173 47.9 46.4 92.5 
< 3 SBM/week and ≥1 of the following 
Rome criteria# for at least 12 weeks 
within the preceding 12 months 
 
*- Rome III criteria which includes straining,  
#
- Part of the Rome III criteria which includes ≥25% straining, incomplete evacuation and hard/lumpy stools,  
$
- 85.32% were male, ¶ 100% were men,  
PRU- Prucalopride, VEL- Velusetrag, TEG- Tegaserod, LUBI- Lubiprostone, ELO- Elobixibat, BIS- Bisacodyl, NaP- Sodium 
Picosulphate, LINA- Linaclotide, MC- Multicenter, SC- Single center, Int- International, I- Intervention, C- Control. 
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Table 2.  Study Quality  (CGR=computer generated randomization; Rx=intervention arm, C=control; LOCF=last observation carried 
forward; PRU=prucalopride, VEL=velusetrag, TEG=tegaserod, LUBI=lubiprostone, ELO=elobixibat, BIS=bisacodyl, NaP=sodium 
picosulphate, LINA=linaclotide)  
Study Identification Drug Generation of randomization sequence 
Allocation 
concealment  
Double 
Blind  
Lost to 
follow up 
Methods used 
for missing data 
Overall 
Quality 
Camilleri 2008 PRU Consecutive numbering + block randomization of 3 + + 5Rx, 3C Imputation High 
Coremans 2003 PRU Unclear Unclear + 0 - Mod 
Ke 2012 PRU CGR  + + 3Rx, 2C NS Mod 
Mueller-Lissner 2010  PRU Randomization code generated by sponsor + + 0 
Considered as 
non-responders High 
Piessevaux 2015 PRU Randomization by web-based/voice-response system. + + 0 Imputation Low 
Quigley 2009 PRU Block randomization of three + + 5Rx, 2C Imputation High 
Tack 2009 PRU Random allocation sequence by the investigator Unclear + 5Rx, 1C 
Considered as 
non-responders High 
Emmanuel 2002 PRU Method not known Unclear + 0Rx, 1C NS Mod 
Yiannnakou 2015 PRU Central interactive web based response system + + 2Rx, 0C Imputation Mod 
Goldberg 2010 VEL 
Telephonic interactive voice response system using a 
permuted block algorithm + + NK LOCF High 
Fried 2007 TEG 
Validated system that automated the random 
assignment by sponsor + + 0 - High 
Kamm 2005 TEG Randomized using  validated computer system + + 26Rx, 10C NS Mod 
Barish 2010 LUBI Block randomization of four + + 4Rx, 1C LOCF Mod 
Fukudo 2015 LUBI Method not known Unclear + 0 - Mod 
Johanson 2008 LUBI Block randomization of four + + 1Rx, 2C LOCF Mod 
Chey 2011 ELO CGR by sponsor + + 1Rx, 0C NS Mod 
Kamm 2011 BIS CGR  + + 0 - High 
Mueller-Lissner 2010 NaP CGR + + 0 - High 
Lembo 2010 LINA CGR using a block size of 5 + + 3Rx, 0C Observed-cases 
approach 
 
Mod 
Lembo 2011 LINA CGR using a block size of 6 + + 29Rx, 4C High 
Lacy 2015 LINA 
Randomization by statistical programmer not 
involved in the trial + + 10Rx, 5C 
Considered as 
non-responders High 
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Table 3.  Pooled RR, and 95% confidence intervals (for network meta-analysis) for primary endpoints (p<0.05 is bolded). (Note: For 
lubiprostone, both of the endpoints are not available +=Superior, -=Inferior).   
 
3A. Responders with ≥3 CSBM per week for the drugs for CIC 
 
Responders with ≥3 CSBM/week 
Placebo 2.46 (1.14, 5.31) 2.83 (1.27, 6.31) 1.84 (1.40, 2.43) 1.47 (0.7, 3.12) 4.86 (1.58, 14.99) 1.96 (0.8, 4.81) 
 
Bisacodyl 1.15 (0.38, 3.49) 0.75 (0.33, 1.69) 0.59 (0.20, 1.75) 1.97 (0.51, 7.72) 0.79 (0.24, 2.60) 
 
Sodium picosulphate 0.65 (0.28, 1.52) 0.52 (0.17, 1.56) 1.72 (0.43, 6.84) 0.69 (0.21, 2.31) 
 
Prucalopride 0.80 (0.36, 1.78) 2.64 (0.83, 8.41) 1.06 (0.41, 2.72) 
 
Tegaserod 3.30 (0.85, 12.79) 1.33 (0.41, 4.30) 
 
Velusetrag 0.40 (0.09, 1.70) 
 
Linaclotide 
 
 3B.  Responders with ≥1 CSBM per week for the drugs for CIC 
Responders with increase over baseline by ≥1 CSBM/week 
Placebo 2.04 (1.3, 3.19) 2.03 (1.27, 3.23) 1.54 (1.30, 1.83) 1.33 (0.97, 1.83) 3.1 (1.61, 5.95) 1.72 (1.0, 2.96) 1.97 (1.09, 3.55) 
 
Bisacodyl 0.99 (0.52, 1.9) 0.76 (0.47, 1.22) 0.65 (0.38, 1.13) 1.52 (0.69, 3.35) 0.84 (0.42, 1.71) 0.96 (0.46, 2.02) 
 
Sodium picosulphate 0.76 (0.46, 1.25) 0.66 (0.37, 1.16) 1.53 (0.69, 3.41) 0.85 (0.42, 1.74) 0.97 (0.46, 2.06) 
 
Prucalopride 0.86 (0.60, 1.23) 2.01 (1.02, 3.93) 1.11 (0.63, 1.97) 1.27 (0.69, 2.35) 
 
Tegaserod 2.33 (1.13, 4.80) 1.29 (0.69, 2.42) 1.48 (0.76, 2.89) 
 
Velusetrag 0.56 (0.24, 1.30) 0.64 (0.26, 1.53) 
 
Linaclotide 1.14 (0.51, 2.55) 
 
Elobixibat 
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Table 4.  Pooled weighted mean difference, and 95% confidence intervals (for network meta-analysis) for Secondary endpoints 
(p<0.05 is bolded). (Note: Tegaserod both of the endpoints are not available, +=Superior, -=Inferior).   
 
4A.  Number of CSBM change from baseline for the drugs for CIC  
  
 
 
 
 
 
 
 
4B.  Number of SBM change from baseline for the drugs for CIC  
# of CSBM/week change from baseline 
Placebo 3.2 (2.37, 4.03) 2.0 (1.19, 2.81) 0.9 (0.52, 1.28) 1.55 (0.90, 2.19) 1.99 (0.77, 3.22) 
 
Bisacodyl -1.2 (-2.36, -0.04) -2.3 (-3.22, -1.38) -1.65 (-2.70, -0.60) -1.21 (-2.69, -0.28) 
 
Sodium picosulphate -1.10 (-1.99, -0.21) -0.45 (-1.48, 0.58) -0.01 (-1.47, 1.46) 
 
Prucalopride 0.65 (-0.10, 1.40) 1.09 (-0.19, 2.38) 
 
Linaclotide 0.44 (-0.94, 1.83) 
 
Elobixibat 
# of SBM/week change from baseline  
Placebo 4.9 (3.90, 5.90) 3.20 (2.28, 4.12) 1.93 (1.45, 2.40) 2.07 (1.12, 3.01) 2.13 (1.54, 2.71) 2.08 (0.76, 3.41) 1.93 (1.30- 2.55) 
 
Bisacodyl -1.7 (-3.05, -0.35) -2.97 (-4.07, -1.87) -2.83 (-4.20, -1.46) -2.77 (-3.93, -1.62) -2.82 (-4.48, -1.16) -2.97 (-4.14- -1.79) 
 
Sodium picosulphate -1.27 (-2.30, -0.24) -1.13 (-2.45, 0.18) -1.07 (-2.16, 0.01) -1.12 (-2.73, 0.49) -1.27 (-2.38- -0.16) 
 
Prucalopride 0.14 (-0.92, 1.20) 0.2 (-0.55, 0.95) 0.15 (-1.26, 1.56) 0 (-0.79- 0.79) 
 
Velusetrag 0.06 (-1.05, 1.17) 0.01 (-1.61, 1.64) -0.14 (-1.27- 0.99) 
 
Linaclotide -0.04 (-1.49, 1.40) -0.2 (-1.05- 0.66) 
 
Elobixibat -0.15 (-1.62- 1.31) 
 
Lubiprostone 
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Table 5.  Quality of Evidence for Responders with ≥1 CSBM  
(# -Inconsistency, ## -Severe inconsistency, $ -Indirectness, $$ -Severe indirectness, * - Imprecision, **- Severe imprecision, § -Risk of bias, p<0.05 is bolded)  
 
Comparison Direct Quality of evidence Indirect Quality of evidence Network Quality of evidence 
Bisacodyl v Placebo 2.04 (1.62, 2.57) High - - 2.04 (1.3, 3.19) High 
Na P v Placebo 2.03 (1.56, 2.64) High - - 2.03 (1.27, 3.23) High 
Prucalopride v Placebo 1.54 (1.28, 1.86) Moderate§ - - 1.54 (1.30, 1.83) Moderate§ 
Tegaserod v Placebo 1.32 (1.14, 1.52) High - - 1.33 (0.97, 1.83) High 
Velusetrag v Placebo 3.1 (1.83, 5.24) High - - 3.1 (1.61, 5.95) High 
Linaclotide v Placebo 1.72 (1.18, 2.52) High - - 1.72 (1.0, 2.96) High 
Elobixibat v Placebo 1.97 (1.26, 3.07) Moderate§ - - 1.97 (1.09, 3.55) Moderate§ 
Na P v Bisacodyl - - 0.99 (0.52, 1.9) High 0.99 (0.52, 1.9) Low** 
Prucalopride v Bisacodyl - - 0.76 (0.47, 1.22) Moderate 0.76 (0.47, 1.22) Very Low** 
Tegaserod v Bisacodyl - - 0.65 (0.38, 1.13) High 0.65 (0.38, 1.13) Low** 
Velusetrag v Bisacodyl - - 1.52 (0.69, 3.35) High 1.52 (0.69, 3.35) Low** 
Linaclotide v Bisacodyl - - 0.84 (0.42, 1.71) High 0.84 (0.42, 1.71) Low** 
Elobixibat v Bisacodyl - - 0.96 (0.46, 2.02) Moderate 0.96 (0.46, 2.02) Very Low** 
Prucalopride v Na P - - 0.76 (0.46, 1.25) Moderate 0.76 (0.46, 1.25) Very Low** 
Tegaserod v Na P - - 0.66 (0.37, 1.16) High 0.66 (0.37, 1.16) Low** 
Velusetrag v Na P - - 1.53 (0.69, 3.41) High 1.53 (0.69, 3.41) Low** 
Linaclotide v Na P - - 0.85 (0.42, 1.74) High 0.85 (0.42, 1.74) Low** 
Elobixibat v Na P - - 0.97 (0.46, 2.06) Moderate 0.97 (0.46, 2.06) Very Low** 
Tegaserod v Prucalopride - - 0.86 (0.60, 1.23) Moderate 0.86 (0.60, 1.23) Very Low** 
Velusetrag v Prucalopride - - 2.01 (1.02, 3.93) Moderate 2.01 (1.02, 3.93) Low* 
Linaclotide v Prucalopride - - 1.11 (0.63, 1.97) Moderate 1.11 (0.63, 1.97) Very Low** 
Elobixibat v Prucalopride - - 1.27 (0.69, 2.35) Moderate 1.27 (0.69, 2.35) Very Low** 
Velusetrag v Tegaserod - - 2.33 (1.13, 4.80) High 2.33 (1.13, 4.80) Moderate* 
Linaclotide v Tegaserod - - 1.29 (0.69, 2.42) High 1.29 (0.69, 2.42) Low** 
Elobixibat v Tegaserod - - 1.48 (0.76, 2.89) Moderate 1.48 (0.76, 2.89) Very Low** 
Linaclotide v Velusetrag - - 0.56 (0.24, 1.30) High 0.56 (0.24, 1.30) Low** 
Elobixibat v Velusetrag - - 0.64 (0.26, 1.53) Moderate 0.64 (0.26, 1.53) Very Low** 
Elobixibat v Linaclotide - - 1.14 (0.51, 2.55) Moderate 1.14 (0.51, 2.55) Very Low** 
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Table 6.  Sensitivity analysis based on dose of medication (for primary endpoints NS if RR’s 95%CI overlaps 1, for secondary 
endpoints NS if RR’s 95% CI overlaps 0) 
Drug Responders with ≥3 CSBM 
Responders with  increase over 
baseline by ≥1 CSBM ∆b CSBM/wk ∆b SBM/wk 
Standard Low High Standard Low High  Standard Low High Standard Low High 
Bisacodyl v 
Placebo 
2.46 
(1.81, 
3.35) 
- - 
2.04 
(1.62, 2.57) - - 
3.2 
(2.66, 
3.74) 
- - 
4.90 
(4.14, 
5.66) 
- - 
Na P v Placebo 
2.83 
(1.93, 
4.16) 
- - 
2.03 
(1.56, 2.64) - - 
2.0 
(1.51, 
2.49) 
- - 
3.20 
(2.55, 
3.85) 
- - 
Prucalopride v 
Placebo 
2.04 
(1.59, 
2.62) 
1.31 
(0.56, 
3.04) 
2.23 
(1.74, 
2.85) 
1.54 
(1.24, 1.92) 
1.81 
(1.23, 
2.66) 
1.71 
(1.45, 
2.01) 
0.88 
(0.49, 
1.28) 
1.30 
(0.76, 
1.84) 
0.9 
(0.42, 
1.38) 
1.58 
(0.72, 
2.44) 
1.85 
(0.79, 
2.91) 
1.63 
(0.46, 
2.81) 
Tegaserod v 
Placebo 
1.75 
(1.32, 
2.33) 
1.18 
(0.86, 
1.62) 
- 
1.41 
(1.18, 1.69) 
1.17 
(0.96, 
1.42) 
- - - - - - - 
Velusetrag v 
Placebo 
4.09 
(1.59, 
10.51) 
5.57 
(2.24, 
13.86) 
4.9 
(1.93, 
12.43) 
2.49 
(1.38, 4.46) 
3.33 
(1.91, 
5.80) 
3.5 
(2.01, 
6.10) 
- - - 
1.90 
(1.23, 
2.57) 
2.20 
(1.55, 
2.85) 
2.10 
(1.35, 
2.85) 
Linaclotide v 
Placebo 
1.92 
(1.03, 
3.57) 
- 
2.0 
(1.08, 
3.69) 
1.64 
(1.07, 2.51) - 
1.81 
(1.19, 
2.73) 
1.45 
(1.09, 
1.82) 
1.02 
(0.22, 
1.82) 
1.70 
(1.39, 
2.01) 
1.83 
(1.18, 
2.48) 
- 
2.26 
(1.84, 
2.68) 
Elobixibat v 
Placebo - - - 
2.25 
(1.42, 3.58) 
1.74 
(1.06, 
2.87) 
2.25 
(1.42, 
3.58) 
1.46 
(0.54, 
2.38) 
1.42 
(0.25, 
2.59) 
3.09 
(2.05, 
4.13) 
1.79 
(0.72, 
2.86) 
1.18 
(-0.06, 
2.42) 
3.27 
(2.11, 
4.43) 
Lubiprostone v 
placebo - - - - - - - - - 
1.92 
(1.35, 
2.49) 
- - 
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Drug: Standard dose, Low dose, High dose. Prucalopride: 2mg QD, 1 mg QD, 4mg QD. 
Velusetrag: 30mg QD, 15mg QD, 50mg QD. Tegaserod: 6mg bid, 2mg bid, no high dose. 
Linaclotide: 145/150mcg QD, 75mcg QD, 290/600mcg QD.  
Elobixibat: 10mg QD, 5mg QD, 15mg QD. Lubiprostone: 24mcg bid, no low and high dose. 
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FIGURE LEGENDS 
 
Figure 1: Flow diagram of included studies identified for systematic review. 
Figure 2: Network diagram (CT=clinical trials, P=patients) 
Figure 3: Comparisons between treatment vs. placebo of primary endpoints, ≥3 CSBM/week 
(panel A) or increase over baseline by >1 CSBM/week (panel B), and secondary endpoints, 
change in CSBM from baseline (panel C) and change in SBM from baseline (panel D). 
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Figure 1. Flow diagram of included studies identified for systematic review.  
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Figure 2. Network diagram (CT=clinical trials, P=patients)  
254x190mm (300 x 300 DPI)  
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Figure 3A. Comparisons between treatment vs. placebo of primary endpoints, ≥3 CSBM/week (panel A) or 
increase over baseline by >1 CSBM/week (panel B), and secondary endpoints, change in CSBM from 
baseline (panel C) and change in SBM from baseline (panel D).  
254x190mm (300 x 300 DPI)  
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Figure 3B. Comparisons between treatment vs. placebo of primary endpoints, ≥3 CSBM/week (panel A) or 
increase over baseline by >1 CSBM/week (panel B), and secondary endpoints, change in CSBM from 
baseline (panel C) and change in SBM from baseline (panel D).  
254x190mm (300 x 300 DPI)  
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Figure 3C. Comparisons between treatment vs. placebo of primary endpoints, ≥3 CSBM/week (panel A) or 
increase over baseline by >1 CSBM/week (panel B), and secondary endpoints, change in CSBM from 
baseline (panel C) and change in SBM from baseline (panel D).  
254x190mm (300 x 300 DPI)  
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Figure 3D. Comparisons between treatment vs. placebo of primary endpoints, ≥3 CSBM/week (panel A) or 
increase over baseline by >1 CSBM/week (panel B), and secondary endpoints, change in CSBM from 
baseline (panel C) and change in SBM from baseline (panel D).  
254x190mm (300 x 300 DPI)  
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ABSTRACT  
Objective: To compare efficacy of pharmacotherapies for chronic idiopathic constipation (CIC) 
based on comparisons to placebo using Bayesian network meta-analysis. 
Data Sources: We conducted searches (inception to May 2015) of MEDLINE, EMBASE, 
Scopus and Cochrane Central, as well as original data from authors or drug companies for the 
medications used for CIC.  
Study Selection: Phase IIB and phase III randomized, placebo-controlled trials (RCT) of ≥4 
weeks’ treatment for CIC in adults with Rome II or III criteria for functional constipation; trials 
included at least 1 of 4 endpoints. 
Data Extraction and Synthesis: Two investigators independently evaluated all full text articles 
that met inclusion criteria and extracted data for primary and secondary endpoints, risk of bias 
and quality of evidence. 
Outcomes: Primary endpoints were ≥3 complete spontaneous bowel movements (CSBM)/week 
and increase over baseline by ≥1 CSBM/week. Secondary endpoints were change from baseline 
(∆b) in the number of SBM/week and ∆b CSBM/week.  
Results: Twenty-one RCTs (9189 patients) met inclusion and endpoint criteria: 9 prucalopride, 3 
lubiprostone, 3 linaclotide, 2 tegaserod, 1 each velusetrag, elobixibat, bisacodyl and sodium 
picosulphate (NaP). All pre-specified endpoints were unavailable in 4 polyethylene glycol 
studies. Bisacodyl, NaP, prucalopride and velusetrag were superior to placebo for the ≥3 
CSBM/week endpoint. No drug was superior at improving the primary endpoints on network 
meta-analysis. Bisacodyl appeared superior to the other drugs for the secondary endpoint, ∆b in 
number of SBM/week.   
Page 42 of 72
https://mc.manuscriptcentral.com/gut
Gut
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
Nelson, Camilleri, et al. - 4 - 
 
 
Conclusions: Current drugs for CIC show similar efficacy. Bisacodyl may be superior to 
prescription medications for ∆b in the number of SBM/week in CIC.    
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SUMMARY BOX 
What is already known about this subject? 
-  Fifty percent of patients with chronic idiopathic constipation (CIC) are not completely satisfied 
with treatment, especially with fiber and laxatives. 
-  The number needed to treat (NNT), estimated from placebo-controlled clinical trials in CIC 
comparing pharmacological therapies to placebo, have been reported as follows: osmotic and 
stimulant laxative, NNT 3; lubiprostone, NNT 4; and prucalopride and linaclotide, both NNT 6. 
-  The absence of direct comparisons between different drug classes limits comparison of 
efficacy among treatments.  
What are the new findings? 
-  Current drugs for CIC show similar efficacy for primary endpoints, which were ≥3 complete 
spontaneous bowel movements (CSBM)/week and increase over baseline by ≥1 CSBM/week. 
-  Bisacodyl may be superior to prescription medications for change from baseline (∆b) 
SBM/week in CIC and in comparison with some of the drugs in ∆b CSBM/week.  
How might it impact on clinical practice in the foreseeable future? 
-  Head-to-head trials of active agents are necessary to determine the optimal selection of 
pharmacological agents for CIC. 
-  Alternatively, first line medications for patients with CIC should be according to the 
pathophysiology in order to increase efficacy, such as prokinetics for patients with documented 
slow transit constipation in the absence of rectal evacuation disorders. 
 
  
Page 44 of 72
https://mc.manuscriptcentral.com/gut
Gut
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
Nelson, Camilleri, et al. - 6 - 
 
 
INTRODUCTION 
The estimated global prevalence of chronic idiopathic constipation (CIC) in adults is 
14%.[1] It is usually diagnosed using Rome III symptom criteria,[2] is about twice as common in 
women and more prevalent over 65 years of age, significantly impacts quality of life, and 
constitutes a significant financial burden.[3] Treatment of constipation [4] usually starts with  
nonpharmacological agents like fiber (soluble in preference to nonsoluble fiber and is followed 
by pharmacological agents if there is no response to fiber.[5] Polyethylene glycol, an osmotic 
laxative, increases the mean number of stools per week more effectively than placebo or 
lactulose in adults with CIC, based on direct meta-analyses.[6] It is estimated that about 50% of 
patients with CIC were not completely satisfied with treatment due to lack of efficacy or safety 
concerns, especially with fiber and laxatives (both stimulant and osmotic). 
Therefore, this appraisal of the relative efficacy of pharmacotherapies for chronic CIC is 
clinically relevant. The pharmacological classes of the medications used for CIC are: diphenyl 
methanes or derivatives (bisacodyl and sodium picosulphate), 5-HT4 receptor agonists 
(prucalopride, tegaserod and velusetrag), guanylate cyclas  C receptor agonist (linaclotide), 
chloride channel type 2 opener (lubiprostone) and apical sodium bile acid, (also known as ileal 
bile acid transport) inhibitor (elobixibat).  
The numbers needed to treat (NNT), estimated from placebo-controlled clinical trials 
comparing these medications to placebo in CIC, were reported as follows: osmotic and stimulant 
laxative, NNT 3; lubiprostone, NNT 4; and  prucalopride and linaclotide, both NNT 6.[6] This 
might suggest differences in efficacy of the different drug classes; however, this assessment was 
based on failure to respond to therapy, and vastly different endpoints were used in individual 
studies.  
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The absence of direct comparisons between different drug classes limits comparison of 
efficacy among treatments to the endpoints currently recommended by the US Food and Drug 
Administration and is consistent with those of European Medicines Agency.[7] Therefore, our 
aim was to compare the efficacy of drugs for CIC based on results of each drug compared to 
placebo using Bayesian network meta-analysis and endpoints consistent with current regulatory 
agency recommendations. 
METHODS 
This systematic review and network meta-analysis was performed according to guidance 
provided by the Cochrane Handbook for Systematic Reviews of Interventions [8]. It is reported 
according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) guidelines[9]. We followed an a priori established protocol. 
Search Methods for Identification of Studies 
A thorough database search was done in May 2015, using Ovid MEDLINE In-Process & 
Other Non-Indexed Citations and Ovid MEDLINE (1946 to present), Ovid EMBASE, Scopus 
databases (1988 to 2015) and Ovid Cochrane CENTRAL (to March 2015) for all the drugs used 
for treatment of CIC. An expert librarian (PE) conducted the medical literature search with input 
from the investigators. All the studies for this meta-analysis were identified using a combination 
of subject headings and free text terms including constipation, chronic constipation, functional 
constipation, lubiprostone, linaclotide, plecanatide, bisacodyl, sodium picosulfate (NaP), 
prucalopride, velusetrag, naronapride, polyethylene glycol (PEG), lactulose, elobixibat, fiber, 
and randomized placebo-controlled trial. Terms were searched  in the title, abstract, original title, 
name of substance word, subject heading word, keyword heading word, protocol supplementary 
concept word, rare disease supplementary concept word, and unique identifier. The search was 
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conducted using combinations of these terms by using “and/or”. Multiple different combinations 
of these terms were used. All the abstracts identified using the search strategy were 
independently evaluated by two investigators (AN and NV) in order to select studies that were 
eligible for inclusion. For those studies, full text articles were requested. Additional studies were 
added after review of these drugs in the treatment of CIC in clinicaltrials.gov and manual review 
of the citations in the publications. All the studies were independently identified by two 
investigators using well-defined inclusion criteria; conflicts were resolved by consensus between 
the two investigators after discussing with a third investigator (MC) with content expertise.  
Inclusion Criteria  
This systematic review and network meta-analysis was limited only to randomized, 
placebo-controlled trials of drugs that are either approved by FDA for CIC or drugs with data 
available for at least one pre-specified endpoint from phase IIB or III randomized, placebo-
controlled trials, and  >4 weeks of treatment. Participants included were adults (>18 years of age) 
who satisfied Rome II or Rome III criteria for (chronic) functional constipation.  
There were no exclusions based on gender, sample size, medical condition, language 
limitation or medications that are known to affect colonic transit or minimum follow-up period. 
All eligible studies were required to have placebo as control interv ntion.  
Outcome Assessment 
The current recommended endpoint required by regulatory agencies (specifically, the 
U.S. Food and Drug Administration) for demonstration of efficacy in CIC trials is ≥3 complete 
spontaneous bowel movements (CSBM)/week and increase over baseline by ≥1 CSBM/week in 
9 out of 12 weeks of treatment. However, only randomized, placebo-controlled trials of 
linaclotide included this endpoint; therefore, we analyzed different endpoints that addressed 
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similar outcomes, in order to be consistent in appraising efficacy among studies. The primary 
endpoints were the proportion of responders, based on ≥3 CSBM)/week or the proportion of 
responders with increase over baseline by ≥1 CSBM/week.  The secondary endpoints were 
continuous, quantitative variables: the change from baseline (∆b) in the number of spontaneous 
bowel movements (SBM)/week and ∆b CSBM/week. Unfortunately, none of the four available 
PEG trials included the endpoints selected for our network meta-analysis. 
Data Extraction and Management   
Data extraction from the eligible studies was performed by two independent investigators 
(AN and SC) for the primary and secondary endpoints. Authors of the original publications were 
contacted by email or by phone requesting missing data in the eligible studies. Data were 
extracted from manuscripts or databases provided by the investigators or drug companies. Data 
for primary endpoints were extracted as number of responders and non-responders for each 
primary endpoint and mean and standard deviation for secondary endpoints.  
We also collected data about characteristics of the randomized, placebo-controlled trials, 
such as study center location (by continents); total number, age and gender of participants in the 
intervention and control groups; type of intervention; duration of therapy; and criteria for a 
diagnosis of constipation. Finally, data were extracted to appraise study quality, such as method 
used for analysis of missing data and loss of follow-up in the intervention and control groups.  
Statistical Analysis 
We calculated relative risk for dichotomized outcomes, weighted mean difference 
(WMD) for continuous outcomes, and related confidence intervals. We performed head-to-head 
comparisons using DerSimonian-Laird random-effects model. We assessed statistical 
heterogeneity using the I2 statistic, which represents the proportion of heterogeneity that is not 
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the result of chance, but reflects true differences across study populations and interventions; I2 
>50% indicates substantial heterogeneity. Direct comparisons were performed using RevMan 
v5.3 (The Nordic Cochrane Centre Copenhagen, Denmark). 
Network meta-analyses were used to combine effect sizes for all possible comparisons 
(direct and indirect), regardless of whether they had been compared in trials. In contrast to 
traditional meta-analyses, which compare one intervention with another one at a time and 
combine evidence directly from head-to-head clinical trials (if such trials exist), the network 
meta-analyses allow comparison of all interventions simultaneously. A multivariate meta-
regression model developed by White was used.[10] The network meta-analyses were conducted 
using the “network” suite in Stata Version 14.0 (StataCorp LP, College Station, TX, USA).[10]   
Sensitivity Analysis 
We examined the effects of the drugs for CIC based on relative risks of the primary and 
secondary endpoints. We evaluated effect sizes based on therapeutic dose (standard dose group 
versus high dose) and study quality for prucalopride (low risk of bias versus high risk of bias) for 
CIC treatment. We also applied the “leave-one-out” method by excluding one study of 24 weeks 
duration to evaluate the robustness of our findings.   
Assessment of Risk of Bias and Publication Bias 
Risk of bias was assessed using Cochrane Handbook for Assessing the Risk of Bias [9].  
Two investigators (AN and PV) independently assessed the randomization schedule, allocation 
concealment, blinding of participants and investigators, blinding of outcome assessment, 
methods used for missing data, selective reporting, incomplete outcome data, risk of bias for 
primary and secondary endpoints, and loss of follow up during the treatment period. Due to the 
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limited number of studies included in the analyses, we were not able to evaluate potential 
publication bias.[11]  
Quality of Evidence 
We used the Grading of Recommendation, Assessment, Development and Evaluation 
(GRADE) Approach to rate the quality of evidence for the estimates derived from the network 
meta-analyses.[12] Since the studies included were only randomized, placebo-controlled trials, 
the quality of evidence was considered high in the beginning and down rated based on the 
assessment of risk of bias, inconsistency, indirectness, imprecision and publication bias. The 
quality of evidence is rated as high, moderate, low and very low. For indirect estimates, the 
rating usually starts at lowest rating of contributing direct evidence and can be further down 
rated based on imprecision and indirectness (mainly intransitivity, i.e., difference in patient 
populations between studies involved).  
RESULTS 
Search Results 
The search strategy used identified 546 citations and, among these, we identified 114 
articles for review for the full text appraisal. Among the 114 articles, only 18 articles met the 
inclusion criteria; 96 studies did not meet the inclusion criteria, most often because the endpoints 
in the trials were different from the selected primary and secondary endpoints, articles did not 
have original data, or they were nonrandomized studies. The agreement between the 
investigators (AN and NV) for selection of studies after full text review was high (Kappa statistic 
0.86). 
Three studies which were not identified by the search strategy were added by the 
investigators. We contacted the authors and drug sponsors of these studies for additional 
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information regarding the primary and secondary endpoints, and their responses were added to 
the analysis. 
Figure 1 shows the schematic diagram of study selection for the systematic review and 
meta-analysis; in total, 21 studies were eligible. The study characteristics are summarized in 
Table 1.  
There were 9189 patients in the 21 studies: 9 with prucalopride,[13, 14, 15, 16, 17, 18, 
19, 20, 21] 3 with lubiprostone,[22, 23, 24] 3 with linaclotide,[25, 26, 27] 2 with tegaserod,[28, 
29] 1 each with Velusetrag,[30] Elobixibat,[31] bisacodyl,[32] and sodium (Na) 
picosulphate.[33] The number of drugs, sample size of each drug, and the number of clinical 
trials included in the network meta-analysis are represented in the form of a network diagram 
(Figure 2).  
The risk of bias of the included studies is summarized in Table 2. Overall, quality was 
high in 11, moderate in 9, and low in 1 study. Downgrading of quality was based most often on 
unstated details regarding blinding, allocation concealment or management of missing data. 
Direct Meta-analysis 
The results of the direct meta-analysis for each primary and secondary endpoint are 
summarized in Figure 3A-D.  
Primary Endpoints  
The data for responder analysis with ≥3 CSBM/week were available for 14 randomized, 
placebo-controlled trials. All six drugs showed a significant increase in ≥3 CSBM/week when 
compared to placebo. Among the three 5HT4 agonists (prucalopride, velusetrag and tegaserod), 
prucalopride showed higher efficacy [relative risk (RR)] of 1.85 with a 95% confidence interval 
(CI) of 1.35 to 2.54 when compared to placebo and with significant heterogeneity of 80.8% 
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(p=0.0001). Velusetrag had an RR of 4.86 (95% CI, 2.02 to 11.71); the wider confidence interval 
may suggest velusetrag might be less efficacious , was considered inferiorwhen compared to 
prucalopride since the CI is wide. Stimulant laxatives, bisacodyl and NaP, showed approximately 
similar efficacy. For linaclotide, RR was 1.96 (95% CI, 1.12 to 3.44). There was significant 
heterogeneity between studies of all the drugs appraised using this endpoint (I2 = 77.4% P < 
0.00001). 
For responder analysis with increase over baseline by ≥1 CSBM/week, data were 
available for 15 randomized, placebo-controlled trials; all 7 of the drugs were superior to 
placebo. Stimulant laxatives (bisacodyl and NaP) and elobixibat showed approximately similar 
efficacy. Prucalopride showed superior efficacy among the 5HT4 agonists, but the heterogeneity 
between studies was significant (I2 = 74.5%, p=0.0001). Even though the RR for velusetrag was 
3.10, which is relatively high when compared to the RR for prucalopride, the 95% CI with 
velusetrag was wide (1.83 to 5.24) and overlapped that of prucalopride. Given the overlapping 
95% CI for the two drugs and the significant heterogeneity in the efficacy of prucalopride, the 
data show overall similar efficacy for prucalopride and velusetrag.  
Secondary Endpoints  
Data for ∆b CSBM/week were available only for 5 drugs. All the drugs showed superior 
efficacy when compared to placebo. Bisacodyl had a weighted mean difference (WMD) of 3.20 
(95% CI, 2.66 to 3.74). Elobixibat and NaP had similar efficacy. For linaclotide, the WMD was 
1.57, with heterogeneity I2 of 0%; this WMD was greater than that of prucalopride which was 
0.90 and was also associated with significant heterogeneity I2 of 76.8%.    
For the ∆b SBM/week, all 7 of the drugs showed superior efficacy relative to placebo. 
Bisacodyl showed higher efficacy with a WMD of 4.90 when compared to NaP (3.20). 
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Velusetrag, elobixibat and linaclotide showed similar efficacy with a mean difference (MD) in 
the absolute number of ∆b SBM/week of ~2.08. For prucalopride, the WMD was 2.03, with 
significant heterogeneity of 63.9%. For lubiprostone, WMD was 1.91 with an I2 of 23.4%. 
Network Meta-analysis 
Responder analysis for ≥3 CSBM/week (Table 3A)  
Except for tegaserod, all the other drugs (bisacodyl, NaP, prucalopride, velusetrag, 
linaclotide and elobixibat) showed superior efficacy compared to placebo, but none of the drugs 
showed superior efficacy when compared to each other in the network meta-analysis. 
Responder analysis for increase over baseline by ≥1 CSBM/week (Table 3B)  
Apart from tegaserod and linaclotide, all the drugs (bisacodyl, NaP, prucalopride and 
velusetrag) showed superior efficacy when compared to placebo, but none of the drugs showed 
superior efficacy when compared to each other in the network meta-analysis, with the exception 
of velusetrag which appears superior when compared to prucalopride and tegaserod. 
Change in number of CSBM/week compared to baseline (Table 4A) 
Bisacodyl, NaP, prucalopride, linaclotide and elobixibat showed superior efficacy on the 
∆b CSBM/week when compared to placebo. On a network meta-analysis, bisacodyl was superior 
to NaP, prucalopride and linaclotide. Bisacodyl did not show significant efficacy over elobixibat 
using this endpoint. NaP showed superior efficacy when compared to prucalopride.  
Change in number of SBM/week compared to baseline (Table 4B) 
When compared to placebo on a network meta-analysis, bisacodyl, NaP, prucalopride, 
velusetrag, linaclotide, elobixibat and lubiprostone treatment showed superior increase in 
∆b SBM/week.  
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Network meta-analysis suggested that bisacodyl is superior when NaP, prucalopride, 
velusetrag, linaclotide, elobixibat and lubiprostone are compared to bisacodyl. NaP showed 
superior efficacy when prucalopride and lubiprostone were compared to NaP.  
Quality of Evidence 
We applied the GRADE approach to the main outcome of ≥1 CSBM/week because it had 
the largest number of included trials. In terms of direct estimates of drugs compared to placebo, 
the quality of evidence was moderate or high for all comparisons. However, most head-to-head 
comparisons were imprecise (i.e., their CIs were wide and overlapped the null effect). Therefore, 
the quality of evidence of head-to-head comparisons was mostly low (Table 5).  
Sensitivity Analysis 
We conducted sensitivity analyses based on dose of medication (for all drugs for which at 
least two doses were studied) and risk of bias (for prucalopride). Results were consistent between 
standard therapeutic dose group compared to high and low dose groups for the primary endpoints 
and for most of the secondary endpoint analyses (Table 6). An exception was that low dose (in 
contrast to standard or high dose) prucalopride was not eff ctive compared to placebo for the 
endpoints of ≥3 CSBM/week and ∆b SBM/week.  
When analysis was restricted to prucalopride studies at low risk of bias, four trials[13, 16, 
18, 19] were included and, for the two primary responder analyses, we noted that for 
>3 CSBM/week, the RR was 2.12 (1.71, 2.63) and, for increase over baseline by >1 
CSBM/week, the RR was 1.76 (1.54, 2.02); both had heterogeneity of 0%.  
A third sensitivity analysis assessed whether any one study with a markedly different 
duration [17] had a dominant effect on the pooled RR or heterogeneity. We found that this single 
study did not markedly affect the summary estimate for the prucalopride studies. Thus, including 
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the study resulted in RRs for ≥3 CSBM/week and for increase over baseline by ≥1 CSBM/week 
of 1.85 (I2 80.8%) and 1.54 (I2 74.3%), respectively; excluding the study, the RRs were 1.96 (I2 
81.8%) and 1.63 (I2 66.4%), respectively.  
DISCUSSION 
Our study has shown that each drug used in the treatment of CIC is superior to placebo, 
based on the published randomized, placebo-controlled trials. All the drugs are equally 
efficacious for the primary endpoints of responder analysis with ≥3 CSBM/week and increase 
over baseline by ≥1 CSBM/week, in the network meta-analysis. Bisacodyl may be superior to all 
the other drugs in the secondary endpoint of ∆b SBM/week and in comparison with some of the 
drugs in ∆b CSBM/week.  
There are, however, limitations in this appraisal of relatively greater efficacy of 
bisacodyl. There is only one bisacodyl trial with only 4 weeks of treatment compared to other 
drugs which provided treatment for 12 or 24 weeks. Confirmation of superiority of any of these 
pharmacotherapies requires direct comparisons of the active interventions using randomized, 
placebo-controlled trials. A network meta-analysis has distinct features in the absence of trials of 
direct comparisons of treatments, and may inform judicious selection of treatment. The 
International Society for Pharmacoeconomics and Outcomes Research (ISPOR) recommends use 
of multiple treatment meta-analyses in synthesis of data, even with nodal networks, as it allows 
for more statistically sound assessment of comparative efficacy.[34]  
Typically, patients in these randomized, placebo-controlled trials fulfilled Rome II or III 
criteria for constipation after exclusion of medical and structural conditions.[35] These 
symptom-based criteria do not differentiate groups, based on the pathophysiology causing CIC. 
Based on a study of symptoms and pathophysiology in 1411 patients, subgroups of CIC were 
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identified, based on pathophysiology: normal transit constipation (NTC) in ~70%, dyssynergic 
defecation in ~25%, and slow transit constipation (STC) in ~4.5%. [36] In fact, epidemiological 
studies also have shown that about one-third of people in the community who experience 
constipation endorse symptoms consistent with dyssynergic defecation.[4] With a preponderance 
of CIC patients being female and having NTC, the similar efficacy to all the classes of drugs for 
the treatment of CIC is not surprising.  
Prior randomized, placebo-controlled trials included in this analysis did not subgroup 
patients according to pathophysiology; hence, we are unable to report efficacy in subgroups of 
CIC. It is conceivable that patients with STC might respond better to treatment with agents that 
have significant effects on colonic motor function. Several of the agents evaluated in this 
network meta-analysis accelerate colonic transit, including intestinal secretagogues 
(lubiprostone,[37] linaclotide,[38] and the bile acid transport inhibitor, elobixibat [39]) and 
prokinetic agents (prucalopride,[40] tegaserod,[41] and bisacodyl [42]). However, among all 
these drugs, only prucalopride [43] and bisacodyl have been shown to increase the number of 
high amplitude propagated contractions (HAPC), which ar  highly propulsive in the colon.[44]  
Lubiprostone did not induce colonic high amplitude contractions.[45] 
A recent consensus monograph, based on meta-analysis of treatments of CIC, gave strong 
recommendation for treatment with fiber, osmotic laxatives (PEG, lactulose), stimulant laxatives 
(NaP and bisacodyl), prucalopride, linaclotide and lubiprostone.[46] However, the quality of 
evidence was considered moderate in some of the trials, there were no direct comparisons 
between active drugs, and the analysis used as primary endpoint the failure to respond to therapy. 
This appraisal actually combined in non-responder status failure to respond to different endpoints 
in each trial. In addition, the secondary endpoints evaluated did not differentiate SBM from 
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CSBM. Despite these methodological differences, our direct and network meta-analyses confirm 
the general conclusion of the prior report regarding the efficacy of each intervention relative to 
placebo with reference to the primary endpoints (which are the components of the endpoint 
currently recommended by FDA), although there is a possible difference in efficacy on 
secondary endpoints between bisacodyl and other drugs.  
Our study has some limitations. There is only one randomized, placebo-controlled trial 
for 4 of the drugs included in the meta-analysis (NaP, bisacodyl, velusetrag and elobixibat), and 
osmotic laxatives such as PEG, lactulose, and magnesium salts were not included, since the 
endpoints in those studies were not uniform or consistent with the inclusion criteria. This 
particularly applies to the trials with PEG.[47, 48, 49, 50] There is one randomized, placebo-
controlled trial directly comparing PEG3350 + electrolytes (PEG3350+E) to prucalopride 
treatment,[51] but this was a single-center study conducted in a controlled environment on 
patients many of whom had features suggesting evacuation disorder at baseline: ~50% reported 
sensation of anal blockage and 15% manual maneuvers to facilitate defecation. Moreover, the 
primary endpoint was the proportion of patients having ≥3 SCBMs during the last week of 
treatment in a 4-week trial, rather than the entire treatment period, and the randomized, placebo- 
controlled trial showed non-inferiority of PEG3350 + E to prucalopride, consistent with our 
general conclusion that the approved pharmacotherapies for CIC have similar efficacy.  
Other limitations in our network meta-analysis are the variability in the duration of 
treatment (4 to 24 weeks) and safety and adverse events for the drugs were not analyzed in our 
study. Another limitation is that, in many of these pivotal clinical trials, bisacodyl is often used 
as the rescue medication, and the impact of this on the “placebo” arms could not be appraised as 
it is not reported in detail in the trials. It is also conceivable that the high number of prucalopride 
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trials impacted the relative assessment of efficacy by reducing the width of the confidence 
interval of the RR; therefore, we have interpreted cautiously the RR differences between 
prucalopride and velusetrag which was the only medication identified as less efficacious than 
prucalopride in the statistical analysis.   
Strengths in our study design and network meta-analysis include trials with similar 
patient population, comparators, outcome assessments, and trial design; application of the 
GRADE approach to provide an objective and transparent assessment of the quality of evidence 
for evaluating comparative efficacy of these agents;[52] and the inclusion of  the responder 
analyses as well as secondary endpoints which are very relevant in view of differences in 
baseline SBM and CSBM between studies.[53]  
In conclusion, network meta-analysis shows that current pharmacotherapies for CIC have 
similar efficacy. Based on secondary endpoints, bisacodyl may be superior to other medications 
prescribed for CIC; however, bisacodyl is associated with abdominal cramps and diarrhea. In the 
future, head-to-head trials of active agents are necessary to determine the efficacy and adverse 
effects in order to facilitate optimal selection of pharmacological agents for CIC instead of the 
current choice based on failure of prior drugs. 
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Table 1.  Study Characteristics  
Study ID Location Drug 
Doses 
tested 
Study 
Duration      
(weeks) 
Number Total: 
Intervention/ 
control Age (I) Age (C) 
Gender, 
F % Constipation criteria 
Camilleri 
2008 USA PRU 
2mg,  
4 mg QD  12 620: 411/209 48.0±14.3 48.9±13.0 87.1 
≤2 CSBM/week for 6 months, and 
Rome III criteria# 
Coremans 
2003 Belgium PRU 4 mg QD  4 53: 27/26 43.8±2.7 47.4±2.9 98.1 
≥2 of the following for 6 months: 2 
SBM/week and Rome III criteria# 
Ke 2012 
Asia-
pacific PRU 2mg QD  12 501: 249/252 
41.4±12.9
2 41.8±12.9 90 
≤2 SBM/week on average, and ≥1 of 
the following in Rome III criteria* 
Mueller-
Lissner 2010 Int PRU 
1mg, 
2mg,  
4 mg QD  4 300: 230/70 76.5±7.7 76±7.4 70.3 
≤2 CSBM/week for 6 months and ≥1 of 
the following in Rome III criteria# 
Piessevaux 
2015 Europe PRU 2mg QD  24 346: 177/169 49.4±15.8 48.3±16.3 14.7$ 
≤2 CSBM/week and ≥1 of the 
following  in Rome III criteria# for 6 
months  
Quigley 
2009 USA PRU 
2mg,  
4 mg QD  12 641: 429/212 48.9±13.9 46.2±13.0 86.6 
≤2 CSBM/week for 6 months and ≥1 of 
the following in Rome III criteria# for 6 
months 
Tack 2009 Int PRU 
2mg,  
4 mg QD  12 713: 473/240 44.1±15.1 43.7±15.3 90.8 
≤2 CSBM/week for 6 months and ≥1 of 
the following  in Rome III criteria# for 
6 months 
Emmanuel 
2002 UK PRU 1mg QD  4 74: 37/37 NA NA 100 
≤2 SBM/week and need to strain at 
least 25% of the defecation. 
Yiannnakou 
2015 Europe PRU 2mg QD 12 370: 184/186 58.4±17.6 58.5±16.3 0¶ 
≤2 CSBM/week for 6 months and ≥1 of 
the following  in Rome III criteria# for 
6 months 
Goldberg 
2010 USA VEL 
15mg, 
30mg, 
45mg 
QD  4 401: 294/107 44.4±11.7 45.4±10.0 92.0 
≥18 years of age satisfying Rome 3 
criteria functional constipation*  
Fried 2007 Int TEG 6mg bid  12 322: 158/164 51.1±17.1 51.8±17.2 0¶ 
≤3 CSBM/week and ≥1 of the 
following in Rome III criteria# for 6 
months 
Kamm 2005 Int TEG 
2mg, 
6mg bid  12 1264: 848/416 46.3±15.2 46.0±15.6 86.3 
≤3 CSBM/week and ≥1 of the 
following in Rome III criteria# for 6 
months 
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Barish 2010 USA LUBI 
24mcg 
bid  4 237: 119/118 NK NK 88.2 
≤3 SBM/week and ≥1 of the following 
in Rome III criteria# for 6 months 
Fukudo 
2015 Japan LUBI 
24mcg 
bid  4 124: 62/62 42.7±16.4 41.5±14.2 88 
Rome III criteria*, fewer than 3 
defecations per week. 
Johanson 
2008 USA LUBI 
24mcg 
bid  4 244: 120/124 48.0±12.3 49.1±12.9 89.7 
≤3 SBM/week and ≥1 of the following 
in Rome III criteria# for 6 months 
Chey 2011 USA ELO 
5, 10, or 
15mgQD  4 190: 143/47 47.6 49.9 89.5 
<3 CSBM/week and ≥2 of the 
following in Rome III criteria* 
Kamm 2011 UK BIS 
10mg 
QD 4 356: 239/117 55.8±15.9 54.7±15.1 74.7 
< 3 CSBM/week and ≥1 of the 
following in Rome III criteria# for 6 
months 
Mueller-
lissner  2010 Germany NaP 
10mg 
QD  4 362: 229/133 50.2±17.2 51.9±16.5 77.7 
< 3 CSBM/week on average and ≥1 of 
the following  in Rome III criteria# for 
6 months 
Lembo 2010 USA LINA 
75, 150, 
300, or 
600mcg 
QD  4 307: 239/68 47.6±13.1 46.1±15.6 92 
<3 SBM/week and ≥1 of the following  
in Rome III criteria# at least 12 weeks 
during the 12 months preceding the 
study 
Lembo 2011 
  
USA LINA 
145 or, 
290mcg, 
QD  
 
12 643: 434/209 47.4±14.2 49.3±14.3 87.4 < 3 SBM/week and ≥1 of the following 
Rome criteria# for at least 12 weeks 
within the preceding 12 months LINA 12 633: 418/215 47.2±12.8 47.0±13.5 90.4 
Lacy 2015 USA LINA 12 487: 314/173 47.9 46.4 92.5 
< 3 SBM/week and ≥1 of the following 
Rome criteria# for at least 12 weeks 
within the preceding 12 months 
 
*- Rome III criteria which includes straining,  
#
- Part of the Rome III criteria which includes ≥25% straining, incomplete evacuation and hard/lumpy stools,  
$
- 85.32% were male, ¶ 100% were men,  
PRU- Prucalopride, VEL- Velusetrag, TEG- Tegaserod, LUBI- Lubiprostone, ELO- Elobixibat, BIS- Bisacodyl, NaP- Sodium 
Picosulphate, LINA- Linaclotide, MC- Multicenter, SC- Single center, Int- International, I- Intervention, C- Control. 
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Table 2.  Study Quality  (CGR=computer generated randomization; Rx=intervention arm, C=control; LOCF=last observation carried 
forward; PRU=prucalopride, VEL=velusetrag, TEG=tegaserod, LUBI=lubiprostone, ELO=elobixibat, BIS=bisacodyl, NaP=sodium 
picosulphate, LINA=linaclotide)  
Study Identification Drug Generation of randomization sequence 
Allocation 
concealment  
Double 
Blind  
Lost to 
follow up 
Methods used 
for missing data 
Overall 
Quality 
Camilleri 2008 PRU Consecutive numbering + block randomization of 3 + + 5Rx, 3C Imputation High 
Coremans 2003 PRU Unclear Unclear + 0 - Mod 
Ke 2012 PRU CGR  + + 3Rx, 2C NS Mod 
Mueller-Lissner 2010  PRU Randomization code generated by sponsor + + 0 
Considered as 
non-responders High 
Piessevaux 2015 PRU Randomization by web-based/voice-response system. + + 0 Imputation Low 
Quigley 2009 PRU Block randomization of three + + 5Rx, 2C Imputation High 
Tack 2009 PRU Random allocation sequence by the investigator Unclear + 5Rx, 1C 
Considered as 
non-responders High 
Emmanuel 2002 PRU Method not known Unclear + 0Rx, 1C NS Mod 
Yiannnakou 2015 PRU Central interactive web based response system + + 2Rx, 0C Imputation Mod 
Goldberg 2010 VEL 
Telephonic interactive voice response system using a 
permuted block algorithm + + NK LOCF High 
Fried 2007 TEG 
Validated system that automated the random 
assignment by sponsor + + 0 - High 
Kamm 2005 TEG Randomized using  validated computer system + + 26Rx, 10C NS Mod 
Barish 2010 LUBI Block randomization of four + + 4Rx, 1C LOCF Mod 
Fukudo 2015 LUBI Method not known Unclear + 0 - Mod 
Johanson 2008 LUBI Block randomization of four + + 1Rx, 2C LOCF Mod 
Chey 2011 ELO CGR by sponsor + + 1Rx, 0C NS Mod 
Kamm 2011 BIS CGR  + + 0 - High 
Mueller-Lissner 2010 NaP CGR + + 0 - High 
Lembo 2010 LINA CGR using a block size of 5 + + 3Rx, 0C Observed-cases 
approach 
 
Mod 
Lembo 2011 LINA CGR using a block size of 6 + + 29Rx, 4C High 
Lacy 2015 LINA 
Randomization by statistical programmer not 
involved in the trial + + 10Rx, 5C 
Considered as 
non-responders High 
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Table 3.  Pooled RR, and 95% confidence intervals (for network meta-analysis) for primary endpoints (p<0.05 is bolded). (Note: For 
lubiprostone, both of the endpoints are not available +=Superior, -=Inferior).   
 
3A. Responders with ≥3 CSBM per week for the drugs for CIC 
 
Responders with ≥3 CSBM/week 
Placebo 2.46 (1.14, 5.31) 2.83 (1.27, 6.31) 1.84 (1.40, 2.43) 1.47 (0.7, 3.12) 4.86 (1.58, 14.99) 1.96 (0.8, 4.81) 
 
Bisacodyl 1.15 (0.38, 3.49) 0.75 (0.33, 1.69) 0.59 (0.20, 1.75) 1.97 (0.51, 7.72) 0.79 (0.24, 2.60) 
 
Sodium picosulphate 0.65 (0.28, 1.52) 0.52 (0.17, 1.56) 1.72 (0.43, 6.84) 0.69 (0.21, 2.31) 
 
Prucalopride 0.80 (0.36, 1.78) 2.64 (0.83, 8.41) 1.06 (0.41, 2.72) 
 
Tegaserod 3.30 (0.85, 12.79) 1.33 (0.41, 4.30) 
 
Velusetrag 0.40 (0.09, 1.70) 
 
Linaclotide 
 
 3B.  Responders with ≥1 CSBM per week for the drugs for CIC 
Responders with increase over baseline by ≥1 CSBM/week 
Placebo 2.04 (1.3, 3.19) 2.03 (1.27, 3.23) 1.54 (1.30, 1.83) 1.33 (0.97, 1.83) 3.1 (1.61, 5.95) 1.72 (1.0, 2.96) 1.97 (1.09, 3.55) 
 
Bisacodyl 0.99 (0.52, 1.9) 0.76 (0.47, 1.22) 0.65 (0.38, 1.13) 1.52 (0.69, 3.35) 0.84 (0.42, 1.71) 0.96 (0.46, 2.02) 
 
Sodium picosulphate 0.76 (0.46, 1.25) 0.66 (0.37, 1.16) 1.53 (0.69, 3.41) 0.85 (0.42, 1.74) 0.97 (0.46, 2.06) 
 
Prucalopride 0.86 (0.60, 1.23) 2.01 (1.02, 3.93) 1.11 (0.63, 1.97) 1.27 (0.69, 2.35) 
 
Tegaserod 2.33 (1.13, 4.80) 1.29 (0.69, 2.42) 1.48 (0.76, 2.89) 
 
Velusetrag 0.56 (0.24, 1.30) 0.64 (0.26, 1.53) 
 
Linaclotide 1.14 (0.51, 2.55) 
 
Elobixibat 
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Table 4.  Pooled weighted mean difference, and 95% confidence intervals (for network meta-analysis) for Secondary endpoints 
(p<0.05 is bolded). (Note: Tegaserod both of the endpoints are not available, +=Superior, -=Inferior).   
 
4A.  Number of CSBM change from baseline for the drugs for CIC  
  
 
 
 
 
 
 
 
4B.  Number of SBM change from baseline for the drugs for CIC  
# of CSBM/week change from baseline 
Placebo 3.2 (2.37, 4.03) 2.0 (1.19, 2.81) 0.9 (0.52, 1.28) 1.55 (0.90, 2.19) 1.99 (0.77, 3.22) 
 
Bisacodyl -1.2 (-2.36, -0.04) -2.3 (-3.22, -1.38) -1.65 (-2.70, -0.60) -1.21 (-2.69, -0.28) 
 
Sodium picosulphate -1.10 (-1.99, -0.21) -0.45 (-1.48, 0.58) -0.01 (-1.47, 1.46) 
 
Prucalopride 0.65 (-0.10, 1.40) 1.09 (-0.19, 2.38) 
 
Linaclotide 0.44 (-0.94, 1.83) 
 
Elobixibat 
# of SBM/week change from baseline  
Placebo 4.9 (3.90, 5.90) 3.20 (2.28, 4.12) 1.93 (1.45, 2.40) 2.07 (1.12, 3.01) 2.13 (1.54, 2.71) 2.08 (0.76, 3.41) 1.93 (1.30- 2.55) 
 
Bisacodyl -1.7 (-3.05, -0.35) -2.97 (-4.07, -1.87) -2.83 (-4.20, -1.46) -2.77 (-3.93, -1.62) -2.82 (-4.48, -1.16) -2.97 (-4.14- -1.79) 
 
Sodium picosulphate -1.27 (-2.30, -0.24) -1.13 (-2.45, 0.18) -1.07 (-2.16, 0.01) -1.12 (-2.73, 0.49) -1.27 (-2.38- -0.16) 
 
Prucalopride 0.14 (-0.92, 1.20) 0.2 (-0.55, 0.95) 0.15 (-1.26, 1.56) 0 (-0.79- 0.79) 
 
Velusetrag 0.06 (-1.05, 1.17) 0.01 (-1.61, 1.64) -0.14 (-1.27- 0.99) 
 
Linaclotide -0.04 (-1.49, 1.40) -0.2 (-1.05- 0.66) 
 
Elobixibat -0.15 (-1.62- 1.31) 
 
Lubiprostone 
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Table 5.  Quality of Evidence for Responders with ≥1 CSBM  
(# -Inconsistency, ## -Severe inconsistency, $ -Indirectness, $$ -Severe indirectness, * - Imprecision, **- Severe imprecision, § -Risk of bias, p<0.05 is bolded)  
 
Comparison Direct Quality of evidence Indirect Quality of evidence Network Quality of evidence 
Bisacodyl v Placebo 2.04 (1.62, 2.57) High - - 2.04 (1.3, 3.19) High 
Na P v Placebo 2.03 (1.56, 2.64) High - - 2.03 (1.27, 3.23) High 
Prucalopride v Placebo 1.54 (1.28, 1.86) Moderate§ - - 1.54 (1.30, 1.83) Moderate§ 
Tegaserod v Placebo 1.32 (1.14, 1.52) High - - 1.33 (0.97, 1.83) High 
Velusetrag v Placebo 3.1 (1.83, 5.24) High - - 3.1 (1.61, 5.95) High 
Linaclotide v Placebo 1.72 (1.18, 2.52) High - - 1.72 (1.0, 2.96) High 
Elobixibat v Placebo 1.97 (1.26, 3.07) Moderate§ - - 1.97 (1.09, 3.55) Moderate§ 
Na P v Bisacodyl - - 0.99 (0.52, 1.9) High 0.99 (0.52, 1.9) Low** 
Prucalopride v Bisacodyl - - 0.76 (0.47, 1.22) Moderate 0.76 (0.47, 1.22) Very Low** 
Tegaserod v Bisacodyl - - 0.65 (0.38, 1.13) High 0.65 (0.38, 1.13) Low** 
Velusetrag v Bisacodyl - - 1.52 (0.69, 3.35) High 1.52 (0.69, 3.35) Low** 
Linaclotide v Bisacodyl - - 0.84 (0.42, 1.71) High 0.84 (0.42, 1.71) Low** 
Elobixibat v Bisacodyl - - 0.96 (0.46, 2.02) Moderate 0.96 (0.46, 2.02) Very Low** 
Prucalopride v Na P - - 0.76 (0.46, 1.25) Moderate 0.76 (0.46, 1.25) Very Low** 
Tegaserod v Na P - - 0.66 (0.37, 1.16) High 0.66 (0.37, 1.16) Low** 
Velusetrag v Na P - - 1.53 (0.69, 3.41) High 1.53 (0.69, 3.41) Low** 
Linaclotide v Na P - - 0.85 (0.42, 1.74) High 0.85 (0.42, 1.74) Low** 
Elobixibat v Na P - - 0.97 (0.46, 2.06) Moderate 0.97 (0.46, 2.06) Very Low** 
Tegaserod v Prucalopride - - 0.86 (0.60, 1.23) Moderate 0.86 (0.60, 1.23) Very Low** 
Velusetrag v Prucalopride - - 2.01 (1.02, 3.93) Moderate 2.01 (1.02, 3.93) Low* 
Linaclotide v Prucalopride - - 1.11 (0.63, 1.97) Moderate 1.11 (0.63, 1.97) Very Low** 
Elobixibat v Prucalopride - - 1.27 (0.69, 2.35) Moderate 1.27 (0.69, 2.35) Very Low** 
Velusetrag v Tegaserod - - 2.33 (1.13, 4.80) High 2.33 (1.13, 4.80) Moderate* 
Linaclotide v Tegaserod - - 1.29 (0.69, 2.42) High 1.29 (0.69, 2.42) Low** 
Elobixibat v Tegaserod - - 1.48 (0.76, 2.89) Moderate 1.48 (0.76, 2.89) Very Low** 
Linaclotide v Velusetrag - - 0.56 (0.24, 1.30) High 0.56 (0.24, 1.30) Low** 
Elobixibat v Velusetrag - - 0.64 (0.26, 1.53) Moderate 0.64 (0.26, 1.53) Very Low** 
Elobixibat v Linaclotide - - 1.14 (0.51, 2.55) Moderate 1.14 (0.51, 2.55) Very Low** 
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Table 6.  Sensitivity analysis based on dose of medication (for primary endpoints NS if RR’s 95%CI overlaps 1, for secondary 
endpoints NS if RR’s 95% CI overlaps 0) 
Drug Responders with ≥3 CSBM 
Responders with  increase over 
baseline by ≥1 CSBM ∆b CSBM/wk ∆b SBM/wk 
Standard Low High Standard Low High  Standard Low High Standard Low High 
Bisacodyl v 
Placebo 
2.46 
(1.81, 
3.35) 
- - 
2.04 
(1.62, 2.57) - - 
3.2 
(2.66, 
3.74) 
- - 
4.90 
(4.14, 
5.66) 
- - 
Na P v Placebo 
2.83 
(1.93, 
4.16) 
- - 
2.03 
(1.56, 2.64) - - 
2.0 
(1.51, 
2.49) 
- - 
3.20 
(2.55, 
3.85) 
- - 
Prucalopride v 
Placebo 
2.04 
(1.59, 
2.62) 
1.31 
(0.56, 
3.04) 
2.23 
(1.74, 
2.85) 
1.54 
(1.24, 1.92) 
1.81 
(1.23, 
2.66) 
1.71 
(1.45, 
2.01) 
0.88 
(0.49, 
1.28) 
1.30 
(0.76, 
1.84) 
0.9 
(0.42, 
1.38) 
1.58 
(0.72, 
2.44) 
1.85 
(0.79, 
2.91) 
1.63 
(0.46, 
2.81) 
Tegaserod v 
Placebo 
1.75 
(1.32, 
2.33) 
1.18 
(0.86, 
1.62) 
- 
1.41 
(1.18, 1.69) 
1.17 
(0.96, 
1.42) 
- - - - - - - 
Velusetrag v 
Placebo 
4.09 
(1.59, 
10.51) 
5.57 
(2.24, 
13.86) 
4.9 
(1.93, 
12.43) 
2.49 
(1.38, 4.46) 
3.33 
(1.91, 
5.80) 
3.5 
(2.01, 
6.10) 
- - - 
1.90 
(1.23, 
2.57) 
2.20 
(1.55, 
2.85) 
2.10 
(1.35, 
2.85) 
Linaclotide v 
Placebo 
1.92 
(1.03, 
3.57) 
- 
2.0 
(1.08, 
3.69) 
1.64 
(1.07, 2.51) - 
1.81 
(1.19, 
2.73) 
1.45 
(1.09, 
1.82) 
1.02 
(0.22, 
1.82) 
1.70 
(1.39, 
2.01) 
1.83 
(1.18, 
2.48) 
- 
2.26 
(1.84, 
2.68) 
Elobixibat v 
Placebo - - - 
2.25 
(1.42, 3.58) 
1.74 
(1.06, 
2.87) 
2.25 
(1.42, 
3.58) 
1.46 
(0.54, 
2.38) 
1.42 
(0.25, 
2.59) 
3.09 
(2.05, 
4.13) 
1.79 
(0.72, 
2.86) 
1.18 
(-0.06, 
2.42) 
3.27 
(2.11, 
4.43) 
Lubiprostone v 
placebo - - - - - - - - - 
1.92 
(1.35, 
2.49) 
- - 
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Drug: Standard dose, Low dose, High dose. Prucalopride: 2mg QD, 1 mg QD, 4mg QD. 
Velusetrag: 30mg QD, 15mg QD, 50mg QD. Tegaserod: 6mg bid, 2mg bid, no high dose. 
Linaclotide: 145/150mcg QD, 75mcg QD, 290/600mcg QD.  
Elobixibat: 10mg QD, 5mg QD, 15mg QD. Lubiprostone: 24mcg bid, no low and high dose. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page 71 of 72
https://mc.manuscriptcentral.com/gut
Gut
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
Nelson, Camilleri, et al. - 33 - 
 
 
FIGURE LEGENDS 
 
Figure 1: Flow diagram of included studies identified for systematic review. 
Figure 2: Network diagram (CT=clinical trials, P=patients) 
Figure 3: Comparisons between treatment vs. placebo of primary endpoints, ≥3 CSBM/week 
(panel A) or increase over baseline by >1 CSBM/week (panel B), and secondary endpoints, 
change in CSBM from baseline (panel C) and change in SBM from baseline (panel D). 
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